Adoptive transfer of immunity to rabies virus by Jorgenson, Richard Dean
Retrospective Theses and Dissertations Iowa State University Capstones, Theses andDissertations
1981
Adoptive transfer of immunity to rabies virus
Richard Dean Jorgenson
Iowa State University
Follow this and additional works at: https://lib.dr.iastate.edu/rtd
Part of the Allergy and Immunology Commons, Immunology and Infectious Disease Commons,
and the Medical Immunology Commons
This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University
Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University
Digital Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Jorgenson, Richard Dean, "Adoptive transfer of immunity to rabies virus " (1981). Retrospective Theses and Dissertations. 7181.
https://lib.dr.iastate.edu/rtd/7181
INFORMATION TO USERS 
This was produced from a copy of a document sent to us for microfilming. While the 
most advanced technological means to photograph and reproduce this document 
have been used, the quality is heavily dependent upon the quality of the material 
submitted. 
The following explanation of techniques is provided to help you understand 
markings or notations which may appear on this reproduction. 
1. The sign or "target" for pages apparently lacking from the document 
photographed is "Missing Page(s)". If it was possible to obtain the missing 
page(s) or section, they are spliced into the film along with adjacent pages. 
This may have necessitated cutting through an image and duplicating 
adjacent pages to assure you of complete continuity. 
2. When an image on the film is obliterated with a round black mark it is an 
indication that the film inspector noticed either blurred copy because of 
movement during exposure, or duplicate copy. Unless we meant to delete 
copyrighted materials that should not have been filmed, you will find a good 
image of the page in the adjacent frame. If copyrighted materials were 
deleted you will find a target note listing the pages in the adjacent frame. 
3. When a map, drawing or chart, etc., is part of the material being photo­
graphed the photographer has followed a definite method in "sectioning" 
the material. It is customary to begin filming at the upper left hand corner of 
a large sheet and to continue from left to right in equal sections with small 
overlaps. If necessary, sectioning is continued again—beginning below the 
first row and continuing on until complete. 
4. For any illustrations that cannot be reproduced satisfactorily by xerography, 
photographic prints can be purchased at additional cost and tipped into your 
xerographic copy. Requests can be made to our Dissertations Customer 
Services Department. 
5. Some pages in any document may have indistinct print. In all cases we have 
filmed the best available copy. 
University 
Microfilms 
International 
300 N.  ZEEB RD.,  ANN ARBOR, Ml  48106 
8122528 
JORGENSON, RICHARD DE^VN 
ADOPTIVE TRANSFER OF IMMUNITY TO RABIES VIRUS 
Iowa State University PH.D. 1981 
University 
Microfilms 
I ntorn Stion&l 300 N. Zeeb Road, Ann Arbor, MI 48106 
Adoptive transfer of immunity 
to rabies virus 
by 
Richard Dean Jorgenson 
A Dissertation Submitted to the 
Graduate Faculty in Partial Fulfillment of the 
Requirements for the Degree of 
DOCTOR OF PHILOSOPHY 
Major: Immunobiology 
Approved: 
aIn Charge of Major Wo 
'rofe r-i n-cnarge. 
P gram of Immunobiology
e College 
Iowa State University 
Ames, Iowa 
1981 
Signature was redacted for privacy.
Signature was redacted for privacy.
Signature was redacted for privacy.
ii 
TABLE OF CONTENTS 
Page 
INTRODUCTION 1 
LITERATURE REVIEW 3 
Historical aspects 3 
Morphological description 4 
Factors affecting rabies viral infections 4 
Epidemiology 11 
Vaccines and treatments 13 
Nonspecific resistance to rabies 20 
Specific resistance to infection with rabies virus 23 
Transfer factor 30 
MATERIALS AND METHODS 37 
Experimental Animals 37 
Mice 37 
Rats 37 
Guinea pigs 37 
Hamsters 38 
Raccoons 38 
Striped skunks 38 
Swine 38 
Viruses 39 
Immunization virus 39 
In vivo challenge virus 40 
In vitro lymphocyte stimulation virus 40 
Virus Purification 40 
Animal Inoculation-Sensitization with Rabies Virus 41 
Cell Culture Media 42 
Ficoll-Hypaque Density Gradient Solution 43 
Preparation of Mitogen 43 
Peripheral Lymphocyte Collection and Processing 44 
iii 
Page 
Preparation of Mouse Spleen Cells 45 
Gel Filtration 46 
Quantitative Assays of RNA and Protein 46 
RNA determination 46 
Protein determination 47 
Viral and Immuno Assays 47 
Rabies specific fluorescent antibody test 47 
Antibody concentration assay 48 
Virus concentration 48 
Indirect leucocyte migration inhibition (ILMI) 48 
Lymphocyte proliferation assay 51 
Preparation of Dialyzable TF 52 
Part 1. Preliminary Adoptive Immunization Experiments 
Utilizing Antigen Stimulated TF Preparations 54 
Transfer factor treatments in mice 54 
Transfer factor treatment in guinea pigs 60 
Transfer factor treatments in raccoons and skunks 62 
Part 2: In Vitro and In Vivo Studies utilizing Mouse 
Leukocyte DiaTysates 65 
In vitro stimulation of naive lymphocytes with TF 65 
In vitro assay of the in vivo transfer of immunity 65 
to rabies virus 
Effect of varied doses of TF^,, on resistance to 66 
rabies viral infection 
RESULTS 67 
Gel Filtration of Antigen-Stimulated Lymphokines 67 
Protein and RNA Concentration of TF Preparations 67 
Lymphocyte Proliferation Assay: Mitogen and Antigen 
Stimulation of Lymphocytes 67 
Adoptive Transfer Experimentation in vivo: Preliminary 
Studies 76 
Mice 76 
iv 
Page 
Guinea pigs 83 
Raccoons 83 
Striped skunks 85 
Adoptive Transfer Experimentation in vitro 85 
Effects of TF and antigen on unsensitized lymphocytes 85 
Adoptive Transfer Experimentation in vivo 88 
Effect of TF on lymphocyte proliferation response 88 
Effect of TF on resistance to infection with 
rabies virus 90 
DISCUSSION 93 
LITERATURE CITED 106 
ACKNOWLEDGEMENTS 131 
APPENDIX 132 
Raccoon, Fox, Bat and Skunk Rabies in the United States 132 
Raccoon rabies 133 
Fox rabies 135 
Bat rabies 138 
Skunk rabies 142 
1 
INTRODUCTION 
Rabies is a zoonotic viral disease capable of infecting all warm 
blooded mammals and many birds. Experimentally, the virus has been 
propagated in reptilian cell culture (Wiktor 1971 ^ and Wiktor and Clark 
1972) and transmitted from bats to hamsters with arachnid tissues 
(Reagan et al. 1955). Viral replication has been demonstrated in neural 
tissue, muscle tissue and salivary glands. The virus replicates in 
the cytoplasm of somatic cells and is released by budding, resulting 
in little cytopathic effect. Incubation periods of the disease are 
highly variable, ranging from 5 days to several months. 
Rabies virus can be shed by way of oral, mammary, and urinary 
routes. Traditionally, bites by rabid animals have been considered 
to be the principal means of maintenance and transmission of endemic 
and epidemic disease. In recent years, however, researchers have 
demonstrated that viral infection can occur after exposure by ingestion, 
by aerosol, and by transplacental routes. Viral exposure of mucous 
membranes, eyes, and open wounds can result in infections. Rabies 
transmission after a corneal transplant has been reported (CDC 1979a). 
Early studies have shown that resistance to rabies is related to 
levels of specific neutralizing antibody. More recently it has been 
shown that resistance also can be correlated with the cellular immune 
response (Wiktor et al. 1972, Mozar et al. 1972 and WHO 1973) and that 
this cellular response can be adoptively transferred from immunized 
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donors to naive recipients (Hill 1974 and Tsiang and Lagrange 1980). 
It was the purpose of this study to test the possibility of using 
exogenous lymphocyte extracts and secretions to transfer immunity 
to rabies virus adoptively in various species of laboratory animals 
and epidemiologically important wildlife. 
Lymphocytes were isolated from either peripheral blood samples or 
from the spleens of rabies-immunized animals. Lymphokines were collected 
and partially purified after antigenic stimulation of lymphocyte cultures 
or after freeze-thaw lysis of the lymphocytes. Processed lymphokines, 
believed to have transfer factor (TF) activity, were administered to 
nonimmunized animals which subsequently were challenged with rabies 
virus. In addition, spleen cell cultures from nonimmune mice were 
exposed to a processed lymphokine preparation in the presence of rabies 
antigen as a test for changes in the rates of lymphocyte proliferation. 
The efficacy of the TF treatments in vivo ranged from protection, 
through no effect, to interference with resistance to infection. No 
effect was noted after exposure of spleen cells from nonimmunized mice 
to TF in vitro. 
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LITERATURE REVIEW 
Historical aspects 
Many pestilences, such as smallpox, plague, typhus, and cholera 
that played major roles in the social, economic, and political lives 
of people, now can be controlled effectively. Scarlet fever, diphtheria, 
and poliomyelitis, which have killed thousands of people, have all but 
been eliminated as major health threats in the United States (Burnet 
and White 1972). However, rabies, one of the earliest recognized diseases 
known to mankind, remains a much dreaded and little understood disease. 
Despite the efforts of thousands of researchers throughout the centuries, 
it is still prevalent in many parts of the world. 
Democritus first described rabies in dogs approximately 500 years 
B. C. Aristotle noted the broad host range and zoonotic nature of the 
malady when he wrote, in the fourth century, that all animals become 
diseased when bitten by dogs suffering from the madness (Steele 1975). 
One of the earliest reported cases of sylvatic rabies was that of a 
bear in Lyons, France in 900 A. D. (Irvin 1970). 
Irvin (1970) suggested that rabies was transported to various 
parts of the world by infected dogs carried on the ships of explorers 
and merchants, but Constantine (1971) concluded that vampire bats in 
Central America were infected with rabies virus prior to the discovery 
of America and prior to the widespread transportation of dogs. 
Conquering troops and their livestock perished with rabies-like symptoms 
following bites by these bats. Natives avoided the disease by washing 
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bat wounds and cauterizing them with wood embers. 
In the United States, rabies in dogs was first recorded in Virginia 
as early as 1793. By the beginning of the nineteenth century the 
disease had become well-established in foxes and wolves (Irvin 1970). 
It is unclear today if rabies moved with the westward migration of the 
American settlers or if its recognition and description progressed with 
the movement, but by 1860 it was described as having reached the 
Mississippi River and, in 1899, it was recognized in California (Sikes 
1975). 
Morphological description 
Rabies is a highly fatal disease caused by rabies virus, which is 
classified as a member of the Rhabdoviridae (Melnick and McCombs 1966). 
The virus is an enveloped single-stranded RNA virus with a characteristic 
bullet-shaped morphology (Davies et al. 1963 and Murphy 1975). Surface 
projections 6 nm long with a knoblike structure at the distal end are 
seen on electron micrographs. The projections are not normally seen on 
the planar end of the particles (Hummeler et al. 1967). Mean dimensions 
of rabies virus particles are 180 nm x 74 nm, excluding the surface 
projections (Hummeler et al. 1967 and Sokol et al. 1968). 
Factors affecting rabies viral infections 
The pathogenicity of rabies virus is poorly understood and 
unpredictable. Initially the furious form of the disease is characterized 
by malaise and depression followed by a period of hyperexcitability and 
tetanic spasms of the muscles controlling breathing and swallowing. 
Death may occur during this stage, or these symptoms may be followed by 
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progressive paralysis ultimately leading to death. Paralytic or dumb 
rabies, in which the predominant symptom is a general paralysis and 
in which no stage of hyperexcitability is noted, is also typical. 
The clinical signs of the disease are known to vary with 1) the source 
of the virus, 2) the host species, 3) the age and the sex of the 
infected animal, 4) the inoculation route and dosage, and 5) the 
immunologic state of the host (Dierks 1979). 
Isolates of rabies virus obtained from naturally infected animals 
are considered to be closely related and are classified in a single 
antigenic grouping by nearly all investigators who have studied them 
with modern techniques for viral classification (WHO 1973 and Dierks 1979). 
Highly specific monoclonal antibodies produced by mouse hybridomas failed 
to detect different antigenic specificities in rabies street viruses 
isolated from naturally infected animals in many parts of the world but 
did identify antigenic differences among various laboratory strains 
(Wiktor and Koprowski 1978 and Kaplan and Koprowski 1980). 
Although isolates of street virus are indistinguishable anti-
genically, variations have been reported in the characteristics of 
the disease produced by rabies viruses isolated from different animal 
species. Isolates from spotted skunks (Spiloqale putorius) and Arctic 
wolves (Canis lupus) are characterized by a long incubation period 
in experimental animals and a low pathogenicity in adult mice. In 
natural infections of these two animal species the virus is found to 
have a tropism for lung and muscle tissue and does not produce the 
Negri bodies characteristic of other rabies isolates (Bisseru 1972). 
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These isolates were not recognized as rabies virus prior to the 
development of the suckling mouse test or the rabies fluorescent anti­
body (FA) technique for diagnosis of the disease (Bisseru 1972). 
In addition to variations in the characteristics of infection with 
diverse isolates of virus, the susceptibility of different species 
of animals to infection with a specific viral isolate is variable. It 
has been believed, since the time of Pasteur, that isolates of rabies 
virus propagated in one animal species are more lethal to the homologous 
species than to an unrelated species. For example, Sikes (1962) 
determined that foxes were 100 times more susceptible to infection with 
rabies street virus of fox origin than were skunks. However, Parker 
and Wilsnack (1966) inoculated 30 foxes and 30 skunks with an isolate 
from a skunk and found no significant difference between the susceptibility 
of the two recipient species. They did observe longer incubation periods 
and higher titers of virus in salivary secretions of skunks as compared 
to fox salivary secretions. Bats and mustelids are reported to develop 
subclinical infections with rabies virus but this rarely occurs in dogs 
(Bisseru 1972). 
Sikes (1975) identified rodent and lagomorph species as being 
either extremely susceptible or highly susceptible to rabies infection. 
Winkler et al. (1972) inoculated groups of gray squirrels, kangaroo 
rats, and cactus mice with rabies viral isolates of bat, raccoon, or 
fox origin and found that gray squirrels were highly susceptible to 
rabies virus of raccoon origin and much less susceptible to infection 
with rabies virus of bat origin. Kangaroo rats were highly susceptible 
to the fox rabies isolate; cactus mice were 20 times more resistant 
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to infection with the virus inoculum of fox origin than were the 
kangaroo rats. 
Historically, birds have been considered to be rabies-resistant. 
However, naturally acquired clinical rabies infections in birds have 
been reported (Schneider and Burtscher 1967 and DuBose 1972). Von Lote 
(1904) considered chickens and pigeons to have been more resistant to 
experimental rabies infections than were predatory birds. 
Gough and Jorgenson (1976) reported that 23% of predatory birds 
and 2% of nonpredatory birds tested were seropositive for rabies virus. 
All nonpredatory seropositive birds, including the European starling 
(Sternus vulgaris) and the common crow (Corvus brochyrhynchos), were 
scavaging species. Jorgenson et al. (1976) were able to demonstrate 
rabies infection in a great horned owl (Bubo virginianus) after viral 
exposure by the oral route. Seroconversion occurred and virus was 
reisolated, but no clinical signs of infection were noted. 
Younger animals are usually more susceptible to rabies infection 
than are older ones (Sikes 1975). Personnel at the Center for Disease 
Control (CDC) suggest that young cats and dogs are more susceptible 
to the disease and have caused more human exposures to rabies than have 
mature animals (CDC 1979d). The relatively higher sensitivity seen when 
using suckling mice in the rabies mouse inoculation test as compared 
with using weanling mice is well-established (Koprowski1973a and Bisseru 
1972). 
The importance of sexual differences in the susceptibility to 
rabies infection has been investigated. No differences have been seen 
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in laboratory mice (Koprowski 1973a). Bigler et al. (1973) found no 
significant difference in infection rates between male and female raccoons 
in Florida except that a preponderance of infection in adult females 
was seen during the breeding season. This same phenomenon was reported 
by Friend (1968) in foxes in New York and by Verts (1967) in skunks in 
Illinois. Reproductive conditions, such as aggressiveness and physical 
contact associated with mating and territoriality, may result in an 
increased incidence of rabies in both sexes (Ulbrich 1969 and Wandeler 
et al. 1974a, citing Kauker and Zeetl 1960 and 1963). Biting and agres-
siveness during mating of captive striped skunks is considerable and can 
result in bleeding wounds for both sexes. Fighting has been observed 
between males in breeding condition, but fighting was absent when several 
females in estrus were exposed to a single male (Jorgenson and Gough, 
unpublished data). 
Steele (1973) has suggested that clinical rabies in female bats 
may be associated with the stress of gestation and parturition. He 
stated that the greatest stress is associated with lactation and this 
may result in latent infections becoming active rabies cases. 
The bite of a susceptible animal by an infected animal shedding 
virus in its saliva is the usual means of rabies transmission and bites 
inflicted on the head, neck, and hands are more likely to develop into 
fatal infections than are bites to other parts of the body (Sikes 1975). 
The principal reason for this phenomenon is that the head, neck, and hands 
are highly enervated and the primary mode of rabies viral spread in the 
body is along the peripheral nerves to the central nervous system (CNS) 
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(Dean et al. 1963, Johnson 1965 and Baer et al. 1968). Rabies virus 
progresses from the site of inoculation to the CNS via the peripheral 
nerves at a rate of 3 mm per hour (Kaplan 1969). Thus,rabies virus 
inoculated at the distal portions of the nervous system or where there 
is a relatively lower supply of nervous tissue is more likely to be 
inactivated by the host. 
Viral transmission by means other than bite by a rabid animal is 
possible. The transmission of rabies virus by aerosol to humans 
(Irons et al. 1957 and Winkler et al. 1973) and animals (Constantine 
1962 and Fischman and Ward 1968) has been reported. The virus can 
penetrate the unbroken tissues of the eyes, oral and nasal cavities, 
and the surfaces of other mucous membranes (Reagan et al. 1955, 
Robertson and Beauregard 1964, Soave 1966, Fischman 1969 and 
Correa-Giron et al. 1970). Irvin (1970) has suggested that transmission 
of the virus by means other than bite is of primary importance in the 
maintenance of the virus in the endemic sylvatic cycle of the disease. 
The immunological state of the host is an important parameter 
governing the outcome of a rabies viral infection. Natural immunity 
to rabies infection in animals is documented extensively by Bell 
(1975). Detectable levels of protective antibody can be induced in a 
normal host in 7 to 10 days (Atanasiu et al. 1967). If the host's 
immune system has been exposed previously to rabies antigen, antibody 
can be detected as early as 3 days after a secondary exposure. A 
maximum cellular immune response has been reported to occur at 6 to 
8 days after primary stimulation and at 3 days as an anamnestic 
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response (Hill 1974 and Wiktor et al. 1974). Since rabies virus 
characteristically exhibits a relatively long incubation period, about 
1 to 2 months in man (Hattwick 1974), after natural exposure to the 
virus, the immune system of a normal host can, either by natural or 
acquired means, usually inactivate the virus before it replicates in 
the GMS (Oanis and Habel 1972). 
Finally, the action taken by the host can be an important factor 
governing the outcome of exposure to rabies virus. The value of wound 
cleansing by flushing with water ano of cauterization has been known 
since the time of Celsus 100 years A. D. (Parker 1969). Enright et al, 
(1971) have described the relative values of the use of 65 chemical 
compounds in preventing rabies in mice. They found that most of the 
active compounds were solvents or detergents. These compounds were 
only effective when applied locally near the site of viral injection. 
Benensen (1970) states that the most effective rabies prevention is the 
immediate and thorough cleansing of all types of wounds caused by bite 
or scratch by an animal with rabies or suspected of being rabid. In 
cases of exposure to a known rabid animal, he further suggests infiltrating 
the area beneath the wound with rabies hyperimmune serum. This treatment 
should then be followed with the administration of rabies vaccine or 
rabies vaccine and hyperimmune serum, according to the recommendation 
of CDC (Corey and Hattwick 1975 and CDC 1980b) and the World Health 
Organization (WHO 1973). 
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Epidemiology 
The epidemiology of rabies virus in nature, with the ultimate 
goal of its control and eradication, is probably the most reported 
facet of the disease. However, due to the difficulty in recognizing 
and manipulating the myriad of environmental factors affecting the 
transmission and the maintenance of the virus, epidemiology is one of 
the least understood aspects of rabies (Irvin 1970). 
Rabies virus is pathogenic for all poikilothermic animals (Tierkel 
1959 and Kaplan 1969) and experimental infections have been established 
in all mammalian species tested (Irvin 1970). Of the 19 orders of 
mammals, however, only the Garnivora and the Chiroptera are of importance 
as reservoirs of rabies. It is suggested that the Rodentia may be 
important in localized areas (Irvin 1970). The disease is seen in the 
Artiodactyla, Perissodactyla, and Primates but only as incidental 
hosts (Irvin 1970). 
Nonmammalian animals such as birds are occasionally reported as 
rabid; however, cold-blooded animals are generally thought to be refrac­
tory to the virus. Rabies virus has been reported to persist in the brain 
of a tortoise without causing any apparent ill effects (Irvin 1970). 
Wiktor and Clark (1972) reported that the virus can replicate in reptilian 
cell lines originating from a viper snake, a gecko, a lizard, and a turtle. 
Experimental transmission, using insects as vectors, have been largely 
unsuccessful (Bell et al. 1957). However, hamsters have been infected 
with rabies after rectal instillation of a macerated suspension of 
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ticks which had fed on rabid bats (Reagan et al. 1955). 
In the United States prior to 1960 rabies was most often reported 
in domestic animals, with dogs being the species most frequently 
reported rabid. However, with the development of effective rabies 
vaccines, the establishment of vaccination programs, and the control of 
stray dogs, the incidence of rabies in dogs has been reduced considerably. 
In 1953, the year after low egg passage (LEP) chick embryo origin (CEO) 
vaccine for dogs was licensed for use in the United States, 5,688 cases 
of dog rabies were reported in the United States; in 1979, only 194 
cases were reported. Reported cases of rabies in skunks were 319 and 
3,031 in 1953 and 1979, respectively (CDC 1980a). In 1960, for the 
first time since 1938 when rabies became a reportable disease on a 
nationwide basis, the number of reported cases of rabies in wildlife 
surpassed the number of cases reported for domestic animals --1,836 
sylvatic cases and 1,619 domestic animal cases (CDC 1977a). Although 
the change in the relative prevalence of domestic and wildlife rabies, 
as extrapolated from reporting data, may be a result of an increasing 
awareness of the disease in the wild animals, label et al. (1974) 
described a similar change in the relative prevalence of rabies in 
wild and domestic animals in Canada. They suggest that the change in 
the prevalence of rabies in the various animal species is not totally 
a reporting aberration and that wildlife did not play a major role in 
the perpetuation of early epizootics in Canada. 
Wildlife rabies in the United States is manifested primarily in 
the families Procyonidae (raccoons), Canidae (red and gray foxes). 
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Vesperti1ionidae (bats) and Mustelidae (skunks). Animals from these 
families have accounted for 98% of the 29,932 cases of wildlife rabies 
reported during the period from 1970 through 1979 (CDC 19 80a). For 
a review of rabies in raccoons, foxes, bats and skunks in the United 
States refer to Appendix A. 
Vaccines and treatments 
Although the development of Pasteur's vaccine was a significant 
advancement in the attempt to control rabies, modifications have followed 
that have improved the vaccine's safety, potency, and ease of production. 
Several vaccines currently are available but no one product has been 
universally accepted as being superior in every respect (Habel 1973a). 
Basically there are three major types of rabies vaccines, differing 
in the method of viral production: nervous tissue origin (NTO), egg 
embryo origin, and cell culture origin. Habel (1973a)suggested that 
all known strains of rabies virus have basically similar antigenic 
composition and there is no need for the use of local strains of virus 
in vaccines. Wiktor and Koprowski (1978) and Kaplan and Koprowski (1980), 
however, using monoclonal antibodies, have shown that there are some 
antigenic differences among various laboratory strains of rabies virus. 
If significant antigenic differences are found in street virus isolates, 
it may be necessary to produce rabies vaccines derived from virus isolated 
from animals in the geographic area where the vaccines are to be used. 
Rabbies vaccines of NTO are used widely throughout the world. 
Such vaccines primarily are produced by propagation of the virus in 
mice, rabbits, rats, goats, and sheep and are inactivated with phenol 
(Fuenzalida 1973, Karakujumcan et al. 1973, Lepine 1973, Lepine et al. 
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1973, Seligmann 1973 and Selimov and Morogova'1973) or Ultraviolet 
light (Gispen 1973 and Habel 1973b). Only murine NTO rabies vaccines 
are licensed for use in the United States. Nervous tissue origin 
vaccines have a major disadvantage in that a relatively high rate of 
nonspecific paralysis is seen as a result of immunologic factors 
stimulated by contaminating nervous tissue in the vaccine cross-reacting 
with the host's nervous tissues (Tierkel and Sikes 1967). Abnormalities 
were seen in electroencephalograms from 14% of the persons treated with 
NTO vaccines, and neuroparalytic complications occurred in approximately 
1 in 600 vaccinates. The fatality rate following neuroparalytic syndromes 
was 10% to 25% (Applebaum et al. 1953 and Gibbs et al. 1961). 
For veterinary use, Habel (1973a) recommended vaccines containing 
attenuated live virus of CEO. These vaccines are of two major types: 
the LEP described earlier and the high egg passage (HEP). 
Croghan (1970) described the virus for the CEO-LEP vaccine as 
a "wi1d strain" of rabies virus (now termed Flury strain) attenuated by 
100 serial passages in wet chicks, then serially passed intracerebrally 
(IC) in 7 day-old chicken embryos until it became lethal in weanling 
mice only when inoculated IC. For CEO-HEP vaccines further passages 
were made until the virus was lethal only to suckling mice inoculated IC. 
Forty to 50 serial passages are necessary for the production of LEP 
vaccine and 180 passages are used in the production of HEP vaccine 
(Koprowski 1973b). 
The development of CEO rabies vaccine is regarded as a major 
advance in efforts to control rabies in domestic animals, and, indirectly 
in human populations. The advantages of this type of vaccine over that 
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of NTO include a reduction in instances of nonspecific paralysis, a 
reduction in the amount of contaminating nervous tissue, an increase 
in the duration of immunity, a reduction of vaccine bulk, and relative 
ease and safety of production (Croghan 1970). 
Until recently CEO-LEP vaccine was considered safe and effective 
when used for dogs, although it had caused clinical rabies when 
inoculated into cats (Vaugh and Gerhardt 1961, Dean and Guevin 1963 
and Habel 1973a), cattle (Starr 1959 and Habel 1973a), and some other 
animal species (Tierkel 1963 and Koprowski 1973b). In tests of efficacy 
it was shown to protect dogs for at least three years (Sikes et al. 
1971 and Bisseru 1972). However, the use of the vaccine was discontinued 
in 1979 as a result of evidence that it was responsible for several 
cases of vaccine-induced rabies in dogs (CDC 1979c). 
Because CEO-LEP vaccine was lethal for cattle, CEO-HEP vaccine 
was developed. This vaccine was found to be highly effective when used 
in either cattle or cats, as well as in dogs. Although the CEO rabies 
vaccines were significant developments in the attempt to control animal 
rabies, in 1964 Ableseth was able to develop a new strain of rabies vaccine 
virus termed the SAD strain (Street Alabama Dufferin, formerly identified 
as the ERA strain). The SAD virus vaccine was found to be significantly 
more efficacious than were the LEP and HEP vaccines when used to immunize 
cats, cattle, dogs, horses, goats, and sheep (Abelseth 1967 and CDC 
1977b). In addition to being an effective vaccine for domestic animals, 
Correa-Giron et al. (1970) found that mice could be infected with SAD 
rabies virus after inoculation of the buccal and lingual mucosa, the 
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lungs, and the intestines. Furthermore, Black and Lawsen (1970) de­
monstrated that foxes could be vaccinated by the administration of 
large doses of attenuated SAD vaccine by stomach tube. It was later 
shown that foxes were more readily vaccinated via the buccal cavity than 
via the stomach and intestines with this same vaccine (Black and Lawson 
1973). Baer et al. (1971) and Debbie et al. (1972) demonstrated that 
SAD vaccine administered directly into the oral cavity initiated the 
development of serum neutralizing (SN) antibody titers, and foxes, thus 
immunized, resisted challenge for at least 8 weeks post-vaccination. 
Attempts to find an ideal bait material for administration of the 
vaccine to wildlife included such things as vaccine-treated dog biscuits 
(Winkler et al. 1975), eggs (Debbie 1973), and sausage baits (Winkler 
and Baer 1976). 
Although it appeared that the oral vaccination of foxes in the 
wild with the SAD strain of rabies vaccine was feasible, safety testing 
of the vaccine in nontarget species has resulted in a réévaluation of 
its advisability. Winkler et al. (1975) administered the vaccine to 
opossums, cotton rats, hamsters, and chickens. One of the 10 cotton 
rats died of vaccine-induced rabies when given liquid vaccine directly. 
None of the test animals died when the vaccine was incorporated in 
the dog biscuits. In safety testing of the use of lyophilized SAD 
rabies vaccine placed in plastic pouches. Black and Lawson (1980) 
found that laboratory mice could develop active infections with the 
virus. 
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Although the CEO vaccine has greatly reduced the incidence 
of rabies in animals, these vaccines are not effective when used to 
immunize humans. Duck embryo origin vaccine (DEV), developed by Peck 
et al. (1955), was first licensed for use in man in 1957, and, since 
that time, it has been the vaccine that has been used almost exclusively 
for human post-exposure rabies prophylaxis in the United States (CDC 
1976). This vaccine is prepared with a variant of the Pitman-Moore 
strain of rabies virus that was adapted to replicate in embryonated 
duck eggs. The virus is harvested at the fourteenth egg passage for 
use as vaccine (Hoskins 1973). Although it is less antigenic than are 
nervous tissue vaccines, it is relatively safe and has led to prophylactic 
immunization of persons such as veterinarians, animal control personnel, 
and research workers who are in positions where risk of exposure to rabies 
is great (Farrar et al. 1964 and Shipley and Jubelt 1968). One death 
and 4 neurologic complications were reported in the first 50,000 persons 
treated (Rubin et al. 1973). Based on retrospective data from approx­
imately 424,000 persons treated with DEV between 1958 and 1971, Rubin 
et al. (1973) estimated the incidence of major neurological complications 
attributed to the vaccine to be 3.1 cases per 100,000 persons vaccinated. 
Sikes and Larghi (1967) reported that purified neural tissue 
vaccine was superior to DEV when compared in mouse potency, guinea pig 
challenge, and SN tests. However, comparative statistics from CDC 
have shown DEV to be essentially equal to the Semple type (NTO) 
rabies vaccines in preventing human rabies in the United States 
(CDC 1976). 
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Although DEV has proven to be as effective and a ôafer antirabies 
vaccine than are the NTO vaccines, occasional failures to confer 
protection have been observed (Anderson et al. 1966, Dehner 1970 
and Anon. 1978). In addition, a variety of reactions, including 
anaphylaxis, local skin reactions, generalized body aches, abdominal 
pain, nausea, and vomiting, has occurred after its administration 
(Anderson et al. 1960, Kaiser et al. 1965, Cowdrey 1966, Eldred 1966 
and Rubin et al. 1969). 
In trying to determine the reasons for the relatively low 
antigenicity of DEV, Kuwahara and Burgoyne (1978) found that commercially 
prepared DEV contained the enzyme neuraminidase which degraded viral 
antigens. In addition, DEV was found to induce production of 
neuraminidase by the host. Two cell culture vaccines (human diploid 
cell vaccine and primary hamster kidney vaccine) have not been found 
to either contain or induce neuraminidase activity. 
A recent advance in human antirabies treatment was the development 
of techniques for propagating rabies virus in human diploid cell culture. 
With this system, problems associated with immunological responses 
to contaminating nervous tissue and contaminating avian protein are 
circumvented (Prozesky 1978). Wiktor et al. (1973b)were the first 
to report the results of vaccine trials using human diploid cell vaccine 
(WI-38) in humans. Their WI-38 vaccine, inactivated with tri butyl 
phosphate, was administered to 8 persons. Five of the 8 vaccinates 
showed a SN response after 1 inoculation, and 7 of the 8 had a response 
after 2 inoculations. Serum neutralizing titers after 2 inoculations 
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with this vaccine were essentially equal to titers generally reached 
after 14 doses of DEV. A high anamnestic response was found in persons 
previously inoculated with DEV. 
Hafkin et al. (1978), in comparing the WI-38 vaccine with DEV 
in rabies pre-exposure prophylaxis administered WI-38 vaccine to 19 
veterinary students and DEV to 17 others and reported WI-38 to be clearly 
superior to DEV in its ability to induce SN antibody. They found that 
3 doses of the WI-38 vaccine were necessary to induce an adequate rabies 
antibody titer in 100% of the recipients. Adverse reactions were 
reported to be essentially the same with both vaccines. 
Human diploid cell rabies vaccines (HDCV) currently are being 
produced by Merieux Institute in France, Behringwerke in Germany, and 
Wyeth Laboratories in the United States (CDC 1978a). The French and 
German vaccines have been used to treat more than 100,000 persons in 
Europe. The Merieux HDCV has also been licensed for use in the United 
States and has largely replaced the DEV vaccine for rabies post-exposure 
and pre-exposure prophylaxis (CDC 1980d and 1981). 
In a serologic study of 19 persons to determine the active anti­
body response after administration of HDCV alone or in conjunction with 
rabies immune globulin (RIG), Kuwert et al. (1979) found that no 
interference of active immunization occured due to the RIG. Instead, 
an additive effect was seen between passive antibody and actively produced 
antibody. This is especially significant because RIG has been shown to 
suppress the antibody response to other rabies vaccines (Loofbourow 
et al. 1971 and Hattwick 1974). Wiktor and his co-workers found that the 
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administration of 19S and 7S antibody exerted similar effects (Wiktor 
et al. 1971). This inhibitory effect can be partially overcome if 
the number of vaccine doses is increased, if vaccination is started 
15 days after administration of serum, or if immune serum is given 
12-24 hours after vaccination (Wiktor et al. 1971). When hyperimmune 
serum and vaccine are administered for rabies post-exposure treatment, 
21 doses of vaccine plus booster doses on the 10th and 20th day after 
the completion of the initial course of treatment are recommended 
(Corey and Hattwick 1975 and CDC 1980a). When HDCV is used for post­
exposure treatment in conjunction with RIG, no additional booster 
vaccination is necessary (CDC 1980e). 
Nonspecific resistance to rabies 
In further efforts to improve rabies vaccines and treatment regimes, 
Baer and Cleary (1972) found that highly concentrated baby hamster kidney 
(BHK) vaccine markedly reduced mortality from rabies because of its 
ability to induce the in vitro production of interferon (IF). In 1977, 
Baer et al. reported that the addition of IF or an IF inducer to an in­
effective rabies vaccine resulted in a marked increase in protection. 
Mice receiving rabies vaccine containing the inducer polyriboinosinic-
polyribocytidylic acid (poly I-C) and poly-L Lysine with carboxymethyl-
cellulose (poly ICLC) were more resistant to infection than were mice 
treated with vaccine alone. All mice infected with street rabies virus 
(0.03 ml in the footpad) and treated 24 hr later with HDCV in conjunction 
with poly ICLC were protected from rabies. Mice treated with HDCV alone 
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had a significantly higher mortality rate (43.8%). This was essentially 
equal to the mortality rate observed in untreated control mice (49%). 
The effect of the IF inducer poly I-C in reducing the lethality of 
both street virus and fixed strains of rabies virus was evaluated in 
mice and in rabbits by Janis and Habel (1972). They found that 6 daily 
intravenous (IV) treatments with 1.0 yg or 0.5 yg of poly I-C, beginning 
3 to 24 hr before challenge, protected rabbits from fixed strains of the 
virus. Three daily intramuscular (IM) treatments with 0.5 yg, beginning 
3 hr post-viral challenge, protected rabbits inoculated with street 
rabies virus. Mice infected with street virus were protected with a 
single dose of 1.3 yg of poly I-C given either IM or IP 3 hr post-viral 
challenge. Two or more IM treatments given at the same site as the viral 
inoculum were found to be more effective than intraperitoneal (IP) 
inoculations. Protection was seen in mice treated as long as 67 hr 
after injection with street rabies virus. 
Although Janis and Habel (1972) and Baer et al. (1977) were able 
to demonstrate protection from rabies infection in mice and rabbits 
treated with IF inducers, other investigators have reported that the 
IF inducing capacity of poly I-C varies with the host species (Young 
1971 and Turner 1972). Atanasiu and co-workers were able to induce 
high levels of endogenous IF in mice, hamsters and rabbits by IV 
or IP inoculation of inactivated Newcastle disease virus. With 
subsequent IM challenge with control virus strain (CVS) rabies virus 
they found that the rabbits and hamsters were resistant to infection 
but no protection was observed in the mice (Atanasiu et al. 1970). 
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Postic and Fenje (1971) reported similar results and stated that for 
unknown reasons, IF does not penetrate the CNS of mice. 
Young (1971) found that poly I-C does not induce high levels of 
IF in man and, when it is administered at recommended levels as extra­
polated from most animal studies, it would be toxic. However, Fenje 
and Postic (1971) state that the dosage level of poly I-C effective in 
protecting rabbits from rabies in their experiments is within the range 
of doses contemplated for antitumor therapeutic trials in humans. 
They have published results of research in which a single dose of 
0.04 mg of poly I-C inoculated IV or IM provided protection to rabbits 
inoculated IM, with 5, 25, and 125 rabbit LD50 of rabies street virus 
(fox origin). 
Exogenous IF has been used as a post-exposure treatment of animals 
for rabies (Postic and Fenje 1971 and Ho et al. 1974). However, Ho 
et al. stated that at least 70 million units of IF would be needed for 
one treatment in a human adult male exposed to rabies. In addition, 
there is a very short time period after exposure during which TF is 
effective. Recent progress in the development of methods of TF 
production in bacterial or yeast cultures may make the use of exogenous 
IF in the treatment of human rabies feasible. 
Other studies of nonspecific resistance to rabies viral infections 
in mice, rats and guinea pigs have been reported. Haldar et al. (1977) 
treated mice (3 mg), rats (15 mg), and guinea pigs (30 mg) with 
powdered Mycobacterium phlei suspended in veronal buffer. A second 
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group of animals was vaccinated with inactivated rabbit brain rabies 
vaccine. The animals were subsequently challenged at 10, 20 or 30 days 
post-treatment by IM inoculation with rabies virus (CVS). Similar 
resistance to rabies challenge was seen in the 2 groups. No explanation 
of the observed results was given. The non-specific resistance exhibited 
was attributed to "some other factors." 
Banic (1975) reported reduced mortality to rabies infection in 
guinea pigs after 7 days of vitamin C treatments (100 mg/Kg) initiated 
6 hr after inoculation with a lOX rabbit brain suspension of an un­
identified fixed virus. Nonspecific environmental factors such as 
high ambient temperatures have also been shown to retard replication 
of rabies virus (Clark and Wiktor 1972 and Bell and Moore 1974). 
Specific resistance to infection with rabies virus 
Information concerning the immunologic response to rabies virus 
has been obtained primarily as a result of vaccine trials. It has been 
shown that protection against rabies virus correlated well with the 
concentration of specific serum antibody. The passive administration 
of immune serum has been shown to help prevent clinical rabies. 
The protein moieties of rabies virus have been described (Sokol 
et al. 1971, Wiktor 1971, Madore and England 1977 and Zaides et al. 
1979). These proteins— the M protein of the nucleocapsid, the EP2 
and EPS structural proteins, and the G protein of the surface projections — 
do not all elicit production of the same activities of antibody. The 
G protein has been shown to be responsible for eliciting neutralizing 
antibody (Wiktor 1971 and Wiktor et al. 1973a). Rubin et al. (1971) 
and Dierks et al. (1974) identified IgM with in vitro neutralizing 
activity in blood collected from day 10 through day 27 from 39 persons 
treated with a full course of DEV. However, antibody of the IgG class 
is the only antibody considered to offer significant protection in vivo 
against rabies infection (Wiktor et al. 1968, Wiktor et al. 1973a, 
Coe and Bell 1977, Grandien 1977 and Turner 1978). Antibody of the 
lyM class has a higher valence for viral attachment but it is restricted 
to the circulatory system and can not neutralize virus in the tissues. 
Turner (1978) suggested that it might neutralize any extracellular virus 
in contact with blood in bite wounds but stated that this is very 
unlikely. 
No work has been published regarding the presence of secretory 
IgA response to rabies infection or the capacity of IgA to neutralize 
rabies virus. Using the passive hemagglutination PHA test (Gough and 
Dierks 1971) Jorgenson and Gough (unpublished data: Veterinary Medical 
Research Institute, Iowa State University) were able to detect antibody 
in oral secretions from 11 of 15 animals of 6 wildlife species inoculated 
IM with either rabies street (skunk origin) or fixed (SAD) virus. One 
of 2 raccoons (procyon lotor). 2 opossums (Didelphis marsupial is), 1 
of 1 spotted skunk (Spilogale putori us) and 4 of 4 coyotes (Canis latrans) 
had antibody in salivary secretions at titers ranging from 1:2 to 1:256. 
No conclusion was made as to the class of antibody detected. 
Kubes and Gallis (1944) described a phenomenon whereby brain 
tissue from rabid animals, vaccinated animals, or animals recovered 
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from rabies infection was able to neutralize the virus. Bell et al. 
(1966) speculated that the brain neutralizing substance was locally 
produced antibody. Later Gough et al. (1974) characterized this brain 
associated neutralizing substance as immunoglobulin G (IgG). This was 
later confirmed by Coe and Bell (1977) and Bell and Moore (1979), who 
further demonstrated that the antibody originated in the CNS. 
Several serologic techniques are available for the routine detection 
of rabies antibody. It is suggested that various forms of the virus 
neutralization test measure antibody of the IgG class directed against 
the G protein of the virus and do not readily quantitate antibody of 
the IgM class (Grandien 1977). The indirect immunofluorescence procedure 
mainly detects antibody directed against nucleocapsid antigen,.as does 
the complement fixation test (Wiktor 1971, Wiktor et al. 1973a and 
Schneider et al. 1973). The hemagglutination inhibition and PHA 
techniques probably measure antibody directed at surface antigens 
(Grandien 1977). 
In an effort to evaluate the immune mechanisms responsible for 
abortive rabies infections, Wiktor et al. (1972) suppressed the antibody 
response in 12 mice by irradiation. These mice and 12 nonirradiated 
control mice were then inoculated IC with HEP rabies vaccine followed 
2 hr later by intraplantar inoculation with a lethal dose of street 
rabies virus of bat origin. All vaccinated animals survived but 
challenged mice that had not been vaccinated died of rabies infection. 
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This trial suggested that mechanisms other than either circulating 
or CNS-associated rabies antibody mediated the protection seen after 
IC vaccination with HEP. Wiktor's group theorized that survival of the 
irradiated, vaccinated mice was mediated through IF. Although IF 
possibly contributed to the protection, the role of cell-mediated 
immune (CMI) responses must also be considered. 
Mozar et al. (1973) reported the development of a strong CMI 
response in man after vaccination with DEV following exposure to a 
rabid cat. In that same year the World Expert Committee On Rabies 
(WHO 1973) suggested that the stimulation of CMI might be crucial for 
protection from rabies infection. 
To further investigate the role of cellular immunity in rabies 
viral infections. Turner (1973) passively transferred spleen cells from 
immune mice to naive syngeneic mice, and, on subsequent challenge with 
virus, no protection was demonstrated in the recipient animals. Shope 
et al. (1979) reported on the work of Prabhackar who demonstrated that 
immunosuppressed mice inoculated with HEP rabies virus died, but if 
lymphocytes from immune syngeneic mice were given at 4 to 11 days post­
infection, the mortality was reduced from 90% to 37%. 
Using immune rabbit spleen cells, Wiktor et al. (1974) were able 
to demonstrate an in vitro CMI response to rabies virus. Maximum 
stimulation occurred 8 days after immunization and the immunity could 
be detected with cells collected as long as 175 days post-vaccination. 
They reported that purified virions, viral glycoprotein, and "soluble 
antigen" were capable of stimulating transformation of blast cells 
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sensitized with rabies virus, while nucleocapsid was not. 
Hill (1974) showed that a cellular immune response in mice appeared 
as early as 3 days post-inoculation and a maximal cellular response 
occurred at 6 days. He reported a loss of cellular response by day 20, 
but a rapid increase in activity was noted after reinfection at 30 days. 
Live virus was more effective as a primary inducer but the secondary 
response was stimulated equally by live and inactivated virus. These 
findings are similar to those reported by Wiktor et al. (1974 and 1977a). 
Wiktor et al. (1977a) demonstrated that 3-propiolactone-inactivated 
SAD strain rabies virus inoculated IP into mice generated a strong 
cytotoxic T-cell response in spleen cells, with a maximum response 
6 days post-inoculation. The cytotoxic T-cell response seen in vitro 
was abrogated by exposing the culture of lymphocytes to anti-thymus 
antibody and complement prior to the addition of antigen. With 100 
plaque forming units (PFU) of live attenuated HEP and SAD rabies virus 
inoculated IC into mice, maximum cytotoxic responses were seen on day 7 
(Wiktor et al. 1977b). No cytotoxic response was generated in mice 
inoculated IC with 1000 LD50 of street rabies virus of skunk origin. 
Mice inoculated with street virus developed fatal infections, which 
Wiktor and his co-workers suggested was a result of the defective 
operation of the CMI protective mechanisms. 
Possible explanations for the failure of street virus to generate 
a CMI response suggested by Wiktor et al. (1977b) are that the immune 
system was not sufficiently exposed to the virus or that street virus 
does not cause antigenic changes on infected cell surfaces that would 
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be recognized by cytotoxic T-cells. Using the footpad test, Tsiang and 
Lagrange (1980) have since reported in vivo evidence of a CMI response 
in mice to rabies virus of fox salivary gland origin. It was necessary 
to use the Pasteur strain of Mycobacterium bovis (BCG) as adjuvant and 
25 to 50 Hemagglutination units (HAU) as compared with 5 HAU of the 
stimulation inoculum for stimulation in mice sensitized with fixed 
virus. Using street virus, a peak response was seen on day 4 as 
compared with 6 to 8 days when using fixed virus. 
In an attempt to demonstrate a definite correlation between CMI 
and the resistance acquired after immunization against rabies. Turner 
(1979) treated mice with cyclophosphamide monohydrate (Cy) at various 
time periods prior to immunization with HDCV. The mice were subse­
quently challenged (IM) with 5 to 10mouse LD50 of CVS rabies virus. 
Cyclophosphamide is an immunosuppressant with longer lasting effects on 
B lymphocytes and antibody formation than on T lymphocytes and CMI 
responses. He found that protection was inadequate unless immunization 
with rabies vaccine was delayed until recovery of B-cell function and 
that CM I responses alone can not provide adequate protection against 
rabies infection. 
Miller et al. (1978) approached the problem of elucidating the 
relative roles of the humoral and CMI immune responses to rabies virus 
by selective immunosuppression. Suppression of the humoral response 
was accomplished with the use of antibody against the IgM isotype 
(anti-p- antiserum). Anti-y-treated mice failed to produce antibody 
to rabies virus although their T-cell function remained normal as 
demonstrated by the spleen cell proliferative response to Con-A. 
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Suppression of cellular responses was accomplished by inoculation of 
thymectomized and irradiated mice with syngeneic bone marrow cells that 
had been treated with rabbit-anti-mouse thymocyte serum. CMI depression 
was also accomplished with the use of Cy. Both of these procedures, 
unfortunately, impair activities of B lymphocytes as well as those 
of T lymphocytes. 
Immunosuppressed and control mice were inoculated IC with a 
standard dose (10,000 suckling mouse LD50) of HEP rabies vaccine which 
causes subclinical infection in adult mice. Suppression of the 
humoral response resulted in a 50% higher mortality rate than was seen 
with immunocompetent control mice. A 70% higher mortality rate occurred 
with T cell-depleted mice than with immunocompetent control mice. 
Slightly more mice died of rabies when treated with Cy as compared with 
the bone marrow reconstituted mice. This would be expected because Cy 
is known to prevent formation of both B and T lymphocytes. 
Miller et al, (1978) concluded that both B and T lymphocytes 
are intimately involved in controlling rabies viral encephalitis. 
Antibody may be involved in viral neutralization by coating critical 
receptors, in complement-mediated cytolysis and virolysis, and in antibody-
dependent cell-mediated cytotoxicity. Finally, antibody-initiated 
activation of complement could play a role by causing an inflammatory 
response to occur in rabies infected tissues. They suggested that 
helper T-cells were necessary for the production of SN IgG antibody. 
No conclusions were made as to the role of effector T-cells but the 
increased mortality following depletion of T lymphocytes relative to 
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that occurring after depletion of B lymphocytes implies that CMI also 
contributes to recovery from rabies. Wiktor et al. (1977b) have stated 
that the level of effector T-cell function is directly correlated with 
survival following rabies viral infection. 
Although there is considerable controversy as to the exact role 
CMI responses play in protection from rabies infection, evidence has 
been presented to establish that both humoral and cellular responses 
are inseparably involved in the protection observed. 
Transfer factor 
Cells were first shown to mediate Ct.1,1 when Landsteiner and Chase 
(1942), using viable lymphoid cells, transferred reactivity against 
tubuculin from sensitive to normal guinea pigs. Peripheral blood 
leucocytes (94-98% pure lymphocyte suspensions), but not granulocytes 
or other glass-adherent cells, are sufficient to transfer sensitivity 
(Slavin and Garvin 1964). In 1955 Lawrence observed that leucocyte 
extracts were as effective as viable cells in the transfer of CMI-
He termed the active factor(s) "transfer factor" (TF). 
Transfer factor, as originally defined by Lawrence (1955), is the 
material or materials present in viable cells or extracts of immune 
lymphocytes responsible for the transfer of CMI to nonimmune 
recipients. Lawrence (1974) described TF as "a shunt that bypasses 
the stage of active immunization and converts naive lymphocytes to an 
antigen-responsive state." The activity of TF has not been found to be 
limited by species barriers, as shown by in v_i_VQ and in vitro studies 
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(Table 1). Although TF has not been isolated in sufficiently pure form 
to be fully characterized, a number of physicochemical properties and 
functional properties have been ascribed to it (Tables 2 and 3). 
Adoptive transfer of cellular immunity in humans has been accomplished 
using various types of preparations containing or derived from circulating 
blood leucocytes: viable leucocyte concentrates (Lawrence 1949 and 1952), 
leucocyte extracts prepared by lysis with distilled water or by freezing 
and thawing (Lawrence 1954 and Lawrence et al. 1960), enzyme-treated 
(DNase, RNase, DNase+trypsin) leucocyte extracts (Lawrence 1955 and 
1959), and antigen-liberated TF (Graybill et al. 1973). Lawrence and 
Al-Askari (1971) reported that all of these techniques have been applied 
with equal effects. 
Transfer factor(s) have been used extensively in the treatment of 
various disease states in man. Since it was first used in 1970 (Levin 
et al. 1970), bacterial (Anttila et al. 1977, Rubenstein et al. 1977 
and Hastings and Job 1978), viral (Drew et al. 1973, Kohler et al. 
1974, Kackell et al. 1975, Heim et al. 1976 and Mazaheri et al. 1977), 
fungal (Graybill et al. 1973 and Smith et al. 1976), and parasitic 
(Liburd et al. 1972) diseases, as well as neoplasms, have been treated 
with TF with varying degrees of success (Krown et al. 1974, Oettgen 
et al. 1974 and Byers et al. 1976). Transfer factor has had its 
greatest application when used to treat certain cellular immunodeficiency 
states (Goldblum et al. 1973, Levin et al. 1973 and Ammann et al. 1974). 
The TF phenomenon was originally described in man and was not 
observed in other animal systems until 1972 (Burger et al. 1972). 
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Table 1. Transfer of delayed-type hypersensitivity between 
different énimal species 
Species 
Human to Monkey 
Source 
Maddison et al. 1972, Gal lin and 
Kirkpatrick 1974, Kirkpatrick and 
Gallin 1974 and Maddison 1975 
Human to Mouse 
Human to Guinea pig 
Human to Rat 
Human to Dog 
Mouse to Human 
Rat to Human 
Bovine to Human 
Bovine to Monkey 
Bovine to Mouse 
Bovine to Guinea pig 
Bovine to Rabbit 
Bovine to Dog 
Guinea pig to Mouse 
Adler et al. 1970, Palmer and Smith 
1974, Arala-Chaves et al. 1979, 
Brummer et al. 1979 and Schindler and 
Baram 1979 
Lesourd et al. 1979 and Mischak and 
Spitler 1979 
Arrenbrecht et al. 1979 
Tomar and John 1980 
Vich et al. 1979 
Boucheix et al. 1977 
Burger et al. 1979 , Jeter et al. 1979 
and Newell et al. 1979 
Klesius et al. 1975 
Klesius et al. 1978 and Klesius 1979 
Lesourd et al. 1979 
Klesius et al. 1975 
Klesius et al. 1975 
Potter et al. 1974 
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Table 2. Immunobiologic properties of TF 
Property Source 
Endows recipient with specific 
sensitivity of donor 
Extracts or cell-free supernatants 
as effective for transfer as 
viable cells 
Function of T cells 
Nonimmunoglobulin 
Nonanti geni c 
Interacts with but is not 
neutralized by antigen 
Activity not species specific 
Not active sensitization 
(early onset: 4r6 hr) 
Not passive sensitization 
(long duration: years) 
Serial transfer 
Interferon induction 
Does not stimulate antibody 
production 
Lawrence 1955 
Lawrence 1955 
Slavin and Garvin 1964 
and Hattler and Amos 1965 
Baram et al. 1966 
Rapaport et al. 1965 
Lawrence and Pappehheimer 1956 
Adler et al. 1970 
Lawrence and Pappenheimer 1956 
Rapaport et al. 1960 
Lawrence 1955 
Emodi et al. 1973 
Pappenheimer 1956 and 
Good et al. 1957 
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Table 3. Physiocochemical characteristics of TF 
Characteristic Source 
Resistant to lysis by distilled water 
Dialysable 
Lyophilized dialysate stable for 
as long as 5 yrs. at 4 C 
Inactivated at 56 C for 30 min; 
however Spitler et al. (1973)found 
TF resists 56 C for 2 hr 
Resistant to the following enzyme activities: 
Pronase 
However, Burger et al. (1979) 
found TF to be sensitive to pronase. 
DNase 
Pancreatic RNase 
T 1 RNase 
Trypsin 
Destroyed by RNase III 
Positive biuret reaction 
Positive Lowry reaction 
Positive orcinol reaction 
Polypeptide: oligopeptide ratio, 2:1 
Contains approximately 12 amino 
acids and 3-4 RNA bases 
Molecular Wt. 2000-4000 
Density 1.47/g/cm^ 
Net negative charge 
Isoelectric pnt. pl=1.6 
Lawrence 1955 
Lawrence 1955 
Lawrence 1969 
Lawrence and Zweiman 1968 
Spitler et al. 1973 
Lawrence 1959 
Lawrence et al. 1960 
Potter et al. 1974 
Lawrence 1959 
Potter et al. 1974 
Lawrence 1969 
Kirkpatrick and Gal lin 1974 
Baram and Mosko 1965 
Gottlieb et al. 1973 
Gottlieb et al. 1973 
Gottlieb et al. 1973 
Gottlieb et al. 1973 
Potter et al. 1974 
Vandenbark et al. 1977 
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It has since been described in subhuman primates (Maddison et al. 
1972 and Gal lin and Kirkpatrick 1974)» rats (Liburd et al. 1972), 
guinea pigs (Burger et al. 1972 and Rosenfeld and Dressier 1974), 
mice (Palmer and Smith 1974), cattle (Klesius et al. 1975 and Klesius 
and Fudenberg 1977) and dogs (Thilsted and Shifrine 1979). 
The administration of TF by IM and IV routes was found to be 
equally effective when used to immunize guinea pigs against tuberculin 
(Lawrence 1974). Successful transfer of tuberculin sensitivity with oral 
administration of TF has been described (Jeter et al. 1977 and Jeter 
et al. 1979). Systemic versus local transfer of sensitivity is reported 
to be dose dependent (Lawrence and Zweiman 1968). 
Transfer factor is thought to function as an informational molecule, 
causing or uncovering antigen-specific receptors on T-lymphocytes. 
Theoretically, TF may serve as a derepressor of potentially antigen-
responsive lymphocytes or as a TF-antigen complex of increased immuno-
genicity ("superantigen"). The "superantigen" hypothesis is not widely 
accepted because development of immunity in naive animals subsequent to 
treatment with TF occurs too rapidly to be explained as an active response 
elicited by exposure to antigen (Potter et al. 1974). Data obtained 
from equilibrium dialysis of specific TF against specific antisera 
(Baram and Mosko 1965) and the absence of an anamnestic antibody response 
in rhesus monkeys treated with specific TF and subsequently challenged 
with specific antigen (Maddison et al. 1972) further refute this theory. 
In addressing the derepressor hypothesis of Lawrence (1969), 
Potter et al. (1974) state that, although TF is too small to code for 
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specific proteins involved in the immune response, it could function as 
a regulatory element in genetically competent leucocytes. According 
to this theory, the double-stranded RNA moiety of TF would compete 
with a cellular DNA sequence for a specific repressor. The repressor, 
theoretically, would have a greater affinity for the TF molecule than 
for cellular DNA, and specific gene(s) necessary for the production of 
proteins (receptors and/or lymphokines) involved in the immune response 
would be derepressed. Based on the projected theories of size, chemical 
composition, and steric organization of TF, Potter et al. (1974) 
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speculated that 4 different TF molecules could possibly exist to 
account for the specificities observed. 
Although TF has been used either experimentally or clinically in 
man for the last 25 years, reports of adverse effects of its use are 
limited. In studies describing severe adverse reactions in recipients, 
no conclusive evidence to attribute these to the administration of TF 
has been presented (Maddison, 197 5). Some potential hazards that have 
been proposed include: contamination of TF preparations through careless 
handling; stimulation of autoimmunity in the event that the donor may 
have acquired hypersensitivity to histocompatibility antigens of the 
recipient; stimulation of an overwhelming hypersensitivity in recipients 
who are anergic to the organisms causing their disseminated infections 
or to large tumor masses; and the transfer of unwanted hypersensitivities, 
such as poison ivy (Maddison 1975 and Basten et al. 1975). 
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MATERIALS AND METHODS 
Experimental Animals 
Mice 
All outbred mice used in this study were from a colony of 
Swiss-Webster mice which has been maintained at the Veterinary Medical 
Research Institute since 1972. Mice used for virus isolation and 
virus titration procedures were 18-26 days old when inoculated. 
Mice used for adoptive immunization procedures were 28-35 days old. 
Inbred BALB/c breeding stock mice were purchased commercially.^ 
The 5 to 8-week-old mice used as a source of spleen cells for TF and 
for in vitro lymphocyte proliferation assays were raised at the 
Veterinary Medical Research Institute. 
Rats 
Sprague-Dawley descendent outbred rats of mixed sex were purchased 
2 commercially. All rats weighed approximately 275 gm at the time of 
inoculation. 
Guinea pigs 
Guinea pigs were obtained from a random-bred colony maintained 
at the Veterinary Medical Research Institute. Guinea pigs weighed 
M. A. Bioproducts, Walkersville, Maryland. 
2 Bio-Lab Corporation, St. Paul, Minnesota. 
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from 300 to 400 gm when utilized. 
Hamsters 
Syrian hamsters were obtained from a random-bred colony maintained 
at the Veterinary Medical Research Institute. Adult hamsters were 
used for the production of inmune lymphocytes in adoptive immunization 
trials. 
Raccoons 
Raccoons (Procyon lotor), were collected in Story County, Iowa 
with the use of boxtrapsJ 
Striped skunks 
Adult skunks were captured in north central Iowa in box traps by 
2 employees of the Iowa Conservation Commission. These animals were 
surgically descented and maintained in captivity for approximately 
four months prior to being used for evaluation of adoptive immunization. 
Swine 
Adult swine of mixed breeds were used as a source of peripheral 
blood leucocytes for the indirect leucocyte migration inhibition assay. 
Tomahawk Trap Co., Tomahawk, Wisconsin. 
2 Ronald Andrews, Iowa Conservation Commission, Clear Lake, Iowa. 
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Vi ruses 
Immunization virus 
Three sources of rabies virus were used for immunization of animals 
for the production of rabies immune lymphocytes: 1) High egg passage 
rabies virus vaccine of chicken embryo origin was purchased commercially! 
This lyophilized modified live virus (MLV) was reconstituted in sterile 
distilled water according to the manufacturer's directions. 2) CVS-27 
2 rabies virus was purchased commercially and propagated in mice. The 
lyophilized virus material was reconstituted in M-199 culture medium 
and inoculated IM into the right hind leg (RHL). When moribund, the 
mice were killed; their brains were removed and stored at -70 C until 
used. 3) Dried, killed rabies virus of duck embryo origin purchased 
3 commercially was used in experiments to compare the efficacy of 
adoptive immunization alone, vaccine alone, and enhancement of vaccine 
by adoptive immunization in mice. A single dose vial of commercial 
vaccine was reconstituted in 9 ml of sterile distilled water and ' 
dispensed into a 10 ml vaccine vial. The vaccine was prepared on the 
same day it was to be used. 
^Norden Laboratories Incorporated, Lincoln, Nebraska. 
2 American Type Culture Collection, Rockville, Maryland. 
3 Eli Lilly and Company, Indianapolis, Indiana. 
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In vivo challenge virus 
Lyophilized CVS-27 virus was reconstituted in sterile distilled 
water and inoculated (IM) into laboratory mice (0.05 ml). The animals 
were killed when they were moribund, the brain was removed and a 20% 
(W/V) brain tissue suspension was prepared in Medium-199 (M-199) 
containing 100 units of penicillin, 50 yg of kanamycin and 20% fetal 
bovine serum. The suspension was centrifuged at 200 x g to remove 
cellular debris. The supernatant was removed, aliquanted into 10 ml 
vials and stored at -70 C until used. 
In vitro lymphocyte stimulation virus 
2 stimulation antigen (SAD virus) was propagated in baby hamster 
kidney-21 (BHK-21) cell culture to a titer of ic/"^ mouse ICLD50 
and stored at -70 C until purified or used for in vitro production of 
lymphokine. 
Virus Purification 
Rabies virus lymphocyte stimulating antigen was prepared using 
the aluminum phosphate precipitation procedure used in the lymphocyte 
proliferation assay described by Schneider (1973). The purified SAD 
strain of rabies virus used in the lymphocyte proliferation tests 
International Scientific Inc., Gary, Illinois. 
2 Dr. George Baer, Center for Disease Control, Atlanta, Georgia. 
41 
3 
was diluted to 1:10 for optimal stimulation of sensitized spleen cells. 
Animal Inoculation-Sensitization with Rabies Virus 
High egg passage modified live virus vaccine of chicken embryo origin 
was administered to guinea pigs and mice by IM injection. The animals 
were given 2 inoculations 1 week apart. Guinea pigs received 0.5 ml 
and mice received 0.05 ml of the inoculum per inoculation. Ten to 12 
days after the last inoculation the animals were bled and peripheral 
lymphocytes were isolated for in vitro antigen stimulative lymphokine 
production. 
Duck embryo origin rabies virus was reconstituted in 1 ml of sterile 
distilled water and homogenized 1 to 1 with either Freund's complete 
or Freund's incomplete adjuvant.^ Adult BALB/c mice were inoculated 
subcutaneously in each of the hind foot pads with 0.01 ml of the vaccine 
in Freund's complete adjuvant once each week for 3 weeks. A booster 
inoculation with the vaccine incorporated in Freund's incomplete adjuvant 
was administered 1 month after the last of the 3 initial inoculations. 
Control mice were inoculated with Freund's adjuvant diluted 1 to 1 with 
sterile distilled water. Spleen cells were collected 1 week after the 
booster inoculation was given and used for the preparation of dialyzable 
TF or for the lymphocyte proliferation assay. 
A suspension of mouse brain containing live rabies OVS-27 was 
used in the production of virus-stitiiulated lymphocytes. The suspension 
^Bio-Lab Corporation, St. Paul, Minnesota. 
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was inoculated IM into the RHL of mice (0.05 ml), rats (0.25 ml), 
hamsters (0.1 ml) and guinea pigs (0.2 ml). When moribund, the 
animals were bled and peripheral lymphocytes were isolated for in vitro 
release of lymphokine. 
An adult male striped skunk which had been raised in captivity 
was fed a diet of commercial dry dog food and was provided with a 
3.63% solution of levamisol hydrochloride in the drinking water for 
30 days. The animal then was inoculated IM twice with 6-propiolactone 
inactivated CVS-27 rabies virus (10^'® MICLD50) in Freund's complete 
adjuvant in the RHL at 1 week intervals. Seven days after the second 
immunization, a blood sample was collected by cardiac puncture into 
a siliconized blood collection tube containing 1.5 mg ethyl-
enediaminetetraacetic acid (EDTA)/ml blood. The lymphocytes were 
isolated and cultured for in vitro lymphokine production. 
Cell Culture Media 
Roswell Park Memorial Institute medium 1640 (RPMI 1640)^ was 
prepared according to manufacturer's instructions. Penicillin (100 
units/ml) and streptomycin (100 gm/ml) were added and the pH was 
adjusted to 7.6. The medium was filter-sterilized through a 0.22 m 
p 
mi Hi pore filter and fetal bovine serum was added to a final con­
centration of 5%. 
^Gibco Laboratories, Grand Island, New York. 
^Millipore Corporation, Bedford, Massachusetts. 
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Medium-199 (M-199) was prepared according to manufacturer's 
instructions. Penicillin (100 units/ml), streptomycin (lOOygm/ml) 
and kanamycin (50 g/ml) were added and the pH was adjusted to 7.6. 
The medium was filter-sterilized with fetal bovine serum to give a 
final concentration of 20%. 
Ficoll-Hypaque Density Gradient Solution 
Ficoll-hypaque was used for isolation of lymphocytes. It was 
prepared by making a 9% (W/V) solution of Ficoll 400^ in distilled 
2 
water and a 34% (W/V) solution of sodium diatrizoate (hypaque) in 
distilled water. A solution of ficoll-hypaque with a specific gravity 
of 1.078 was obtained by mixing 64 parts of the ficoll solution with 
36 parts of the hypaque solution. After filter-sterilization (0.22 ym) 
the solution was stored at 4 C. 
Preparation of Mitogen 
2 Concanavalin A (Con-A) was reconstituted with RPMI 1640 cell 
culture medium and was used at a rate of>-0.15 ygm/well in the lymphocyte 
proliferation assay. 
Pharmacia, Piscataway, New Jersey. 
2 Sigma Chemical Co., St. Louis, Missouri. 
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Peripheral Lymphocyte Collection and Processing 
Blood samples were collected from all animals, except mice, into 
evacuated tubes containing EDTA as an anticoagulant (1.5 mg/ml blood). 
Alsever's solution (Alsever and Ainslie 1941) (1 ml Alsever's solution 
to 1 ml blood) was found to be a more satisfactory anticoagulant for 
collecting mouse blood. With the use of Alsever's solution during the 
collection of mouse blood, the amount of red blood cell contamination 
of lymphocyte suspensions was greatly reduced. 
Lymphocytes were isolated from the uncoagulated blood sample by 
centrifugation through ficoll-hypaque. Blood samples were diluted 1:1 
with Hank's balanced salt solution (HBSS), pH 7.6. Eight ml of the 
diluted blood were layered onto 4 ml of ficoll-hypaque in siliconized 
17 X 100 mm plastic tube. Blood tubes were centrifuged at 400 x g for 
30 min. Lymphocytes sedimented to the interface between the ficoll-
hypaque and the plasma layer. The cell band was removed and placed in 
a siliconized 12 x 75 mm plastic tube with 5 ml of HBSS. This lymphocyte 
suspension was centrifuged at 200 x g for 10 min. The HBSS was aspirated 
and replaced with 5 ml of fresh solution. The cells were resuspended 
and pelleted once more by centrifugation at 200 x g for 10 min. The 
HBSS was aspirated and replaced with 1 ml of 2x M-199. A viable cell 
count was done using the trypan blue exclusion technique to differentiate 
between living and dead cells 
Antigen stimulated lymphokine production was accomplished by mixing 
the 1 ml of lymphocyte suspension with 2 ml of a suspension of SAD rabies 
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virus, followed by incubation at 37 C for 72 h in a 5% COg atmosphere. 
After incubation, the suspension was centrifuged at 400 x g for 10 min 
to remove cellular debris. The supernatant was removed and stored 
at - 20 C. 
Preparation of Mouse Spleen Cells 
Mice were killed by cervical dislocation, the abdominal area was 
drenched with 70% alcohol and the skin was removed. Mice from which 
serum was to be collected were anesthetized with ether and bled via 
the orbital sinus prior to being killed. Using sterile thumb forceps 
and scissors the peritoneal cavity was opened and the spleen was 
aseptically removed. 
The spleen was placed in a sterile 60 mm tissue culture dish 
containing 5 ml of RPMI-1640 cell culture medium. Spleen cells were 
obtained by teasing the spleen apart with 2 20 ga. x 1 1/2 in. hypodermic 
needles. The cell suspension was gently aspirated and expelled through 
a 16 ga needle and then expelled through a 25wm mesh screen into a 
17 X 100 mm plastic tube. The remaining spleen pulp was washed 2 
additional times in 5 ml of RPMI-1640 medium. 
The spleen cell suspension (about 7.5 ml/tube) was layered on 
4 ml of ficol1-hypaque solution in a 17 x 100 mm plastic tube and 
centrifuged at 400 x g for 20 min. Lymphocytes were aspirated from the 
ficol1-hypaque medium interface and washed by centrifugation in RPMI-1640 
medium at 200 x g for 10 min 
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Following the third wash the cells were resuspended in RPMI-1640 
medium and the cell concentrations were determined using commercial 
blood diluters^ and a hemocytometer. Spleen cell suspensions consisted 
of 95% or higher lymphocytes and the cell viability, as determined 
with the trypan blue exclusion technique, was usually greater than 95%. 
The cell concentration was adjusted to 5 x 10^ viable cells/ml for the 
O 
proliferation assay and 10 viable cells/ml for TF production. 
Gel Filtration 
Partial purification of TF was accomplished using ascending flow 
gel filtration through Sephadex G-10, G-25, or G-50^in a 9 mm x 600 mm 
column. The Sephadex gels were hydrated in phosphate-buffered saline 
pH 7.6. Three ml of lymphokine-rich supernatant were filtered through 
the column at 4 C at a flow rate of 0.8 ml per min with phosphate 
buffered saline (pH 7.6) as the eluant. Fractions were collected in 
2 ml volumes using a LBK fraction collector and monitored at 280 mm. 
The TF fractions were stored at -20 C. 
Quantitative Assays of RNA and Protein 
RNA determination 
The RNA concentration of the TF preparations was measured using 
the orcinol reaction described by Shatkin (1969). RNA standards were 
^Unipette, Becton, Dickinson & Co., Rutherford, New Jersey. 
2 Pharmacia Fine Chemicals, Piscataway, New Jersey. 
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prepared using Grade VI RNA derived from Torula yeast^ and 5-methyl 
resorcinol monohydrate^ was used to prepare the orcinol reagent. 
Protein determination 
The protein concentration of the TF preparations was measured 
using the Peterson (1977) modification of the Lowry technique. 
Standard protein concentrations were prepared using bovine serum 
2 albumin powder. 
Viral and Immuno Assays 
Rabies specific fluorescent antibody test 
Impression smears were made from the cerebral cortex, hippocampus 
and stem areas of the brain of some animals (excluding mice) which died 
during rabies challenge experiments. A single horizontal cross section 
was made through the brains of experimental mice which died during 
in vivo studies of TF activity. Air-dried impression smears of the 
brain sections were fixed in cold (-20 C) acetone for 30 min and 
stored at -20 C prior to staining. The smears were stained with fluores-
3 
cein labeled anti-rabies globulin and examined with ultraviolet 
microscopy for evidence of rabies antigen (Dean and Ableseth 1973). 
Sigma Chemical Co., St. Louis, Missouri. 
2 Reheis Chemical Co., Chicago, Illinois. 
3 BBL Division of Becton, Dickinson and Company, Cockeysville, 
Maryland. 
48 
Antibody concentration assay 
Rabies antibodies in serum samples obtained from immunized mice 
were titrated using the passive hemagglutination (PHA) procedure 
(Gough and Dierks 1971). 
Virus concentration 
The mouse inoculation test as described by Koprowski (1973a) 
was used for virus titration procedures in this study. Tenfold serial 
dilutions of the virus to be titrated were made in RPMI 1640 medium. 
Five mice were inoculated with 1 of 6 dilutions of a 20% (W/V) mouse 
brain suspension. Virus concentrations were calculated using the 
Spearman-Karber Method (Lorenz and Bogel 1973). 
Indirect leucocyte migration inhibition (ILMI) 
Indicator leucocytes One volume of 6% dextran in 85% saline 
was added to 10 volumes of anticoagulated swine blood and the cell sus­
pension was inverted and reverted 5 times._ After gravity sedimentation for 
30 min at 37 C the leucocyte-rich plasma layer was removed by aspiration, 
diluted with 3 volumes of a 0.83% solution of ammonium chloride to remove 
red blood cells, and held at room temperature for 5 min. The cell 
suspension was centrifuged at 200 x g for 10 min. The sedimented 
leucocytes were resuspended in 10 ml of A1sever's solution and centri­
fuged at 200 X g for 15 min. The wash with A1sever's solution was 
repeated once more. This procedure greatly reduced the amount of cell 
clumping observed as compared with that seen after washing cells with 
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other isotonic solutions. The cells were resuspended in M-199 and 
were counted. The viability was determined by using the trypan blue 
O 
exclusion technique. The cell concentration was adjusted to 2 x 10 
viable cells per ml. 
Agar plates Fresh 1% agar was prepared on the day the assay was 
to be run. The agar was hydrated in distilled water by heating in a 
100 C water bath. Once rehydrated, the agar solution was placed in 
a 49 C water bath. Double strength M-199 was heated in the 49 C water 
bath. Equal volumes of the agar solution and the tissue culture medium 
were mixed thoroughly. Two and one-half ml of the M-199 solution 
was pipetted into each well (35 mm diameter) of 6 well tissue culture 
plates and allowed to solidify at room temperature, in order to increase 
the firmness of the agar, the tissue culture plates were refrigerated 
at 4 C until used. Just prior to being used each plate was removed 
from the cold and 3 holes (15 mm apart and 10 mm from one edge of the 
well) were punched in the agar with the use of a sterile 2.6 mm agar 
punch. The agar was removed from each hole with light suction through 
a sterile Pasteur pipette. Holes punched in cold agar were even edged 
consistent in size. 
Indicator cell stimulation Fifty yl of swine peripheral 
O 
leucocyte suspension previously adjusted to 2 x 10 viable cells per 
ml and an equal volume of the supernatant from cell culture lymphocyte 
were placed in plastic tubes. This mixture was incubated at 37 C 
in a 5% COg atmosphere for 90 min to allow for stimulation of indicator 
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cells. The positive control samples consisted of supernatant solution 
from lymphocytes isolated from mice that had been inoculated with 
CVS-27 rabies virus. The negative control sample was a mixture of 
SAD rabies virus (lo/'^ MICLD50/ml) and an equal volume of M-199 
medium. 
Incubation of migration inhibition plates Following the 90 min 
incubation of indicator leucocytes with the supernatant fluids, 10 ml 
of cell suspensions were dispensed into the agar holes. Each 6 
well tissue culture plate contained 5 test samples and 1 negative control 
sample and each sample was tested in triplicate. Positive control 
samples were dispersed throughout the group of test samples. All samples 
were coded by number to ensure objectivity when measuring the distance 
of migration. After the plates were incubated in a 5% COg atmosphere 
at 37 C for 24 hrs, each well was flooded with 2 ml of 7.5% glutaraldehyde 
and held at room temperature for 45 min to fix the indicator cells. 
The glutaraldehyde was rinsed from the wells with distilled water, the 
agar was removed, the wells were rinsed gently with distilled water and 
the plates were allowed to air dry. After they were thoroughly dried, 
the wells were flooded with Giemsa stain for 30 min at room temperature. 
This was followed by one rinse with tap water, and one rinse with 
distilled water, and another drying cycle. During all drying cycles 
the plates were placed on a slight incline to prevent pooling of water 
over the cell layers which would result in a distinct water line after 
staining. 
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Measurement of migration values The distance of migration 
was determined by measuring the distance from the perimeter of the agar 
hole to the perimeter of the migrating cell line. Measurement was 
accomplished with the use of a dissecting microscope equipped with an 
ocular micrometer. The distance of cell migration for the 3 replicates 
was compared statistically,using the Student's t-test, with the 
migration observed in the 3 replicates of the negative control on the 
same plate. A reduced mean migration between the test and negative 
control wells, statistically significant at P<0.05 level, was considered 
to be positive and to indicate the presence of leucocyte migration 
inhibition factor in the test sample. Migration indices were calculated 
by dividing the square of the mean distance of cell migration for the 
test sample by the square of the mean distance of cell migration in 
the negative control sample. 
H/]j _ (mean distance of cell migration of test) 
(mean distance of cell migration of negative control) 
Once t-tests were performed and migration indices were calculated the 
numbered samples were decoded. 
Lymphocyte proliferation assay 
The lymphocyte proliferation assay used was a modification of the 
procedure described by Valentine (1971). Spleen cell suspensions in 
RPMI-1640 and adjusted to 5 x 10^ viable cells/ml were prepared as 
previously described. The cell cultures were set up in quadruplicate 
in 96 well, 6.4 mm flat bottom tissue culture plates. In each well, 
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0.1 ml of the cell suspension (5 x 10^ spleen cells) and 0.1 ml of the 
previously determined optimum concentration of antigen or mitogen were 
dispensed. Appropriate medium and spleen cell controls were included. 
The cultures were incubated at 37 C in a 5% COg humid atmosphere for 
5 to 7 days, depending on the test variation being run. Five hours 
after labeling with 1 y Ci of ^H-thymidine (specific activity 6.7 Ci/m 
mol)J the cultures were freeze-thawed once and harvested with the use 
2 2 of a multiple well aspirator onto glass fiber filters. The glass 
3 fiber filter disks were placed in counting vials containing 5 ml of 
liquifleur solution and the amount of incorporated radiation was 
determined with the use of a Beckman LS-230 liquid scintillation 
4 ounter. 
Preparation of Dialyzable TF 
Transfer factor was isolated using a modification of the procedure 
described by Ascher et al. (1974). This consisted of TF prepared by 
the conventional dialysis of lymphocyte extracts against distilled 
water (TF^^) for in vivo experiments and by dialysis against tissue 
culture medium (TF^^) for in vitro experiments. Mouse spleen cells 
were collected as described earlier and were suspended in sterile 
New England Nuclear, Boston, Massachusetts. 
2 Bell CO, Vineland, New Jersey. 
3 Research Products International Corp., Mt. Prospect, Illinois. 
4 Beckman Instruments, Inc., Fullerton, California. 
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distilled water (2 ml per 10 viable spleen cells) containing 50 ygm/ml 
of bovine pancreatic DNaseJ Two ml aliquots were placed in sterile 
12 X 75 mm plastic tubes and stored at -70 C. When needed for further 
processing, the cells were subjected to 10 cycles of freezing in 
dry ice-alcohol and thawing in a 37 C water bath. The lysate was 
pipetted into a 0.64 cm diameter dialysis tubing and the tubing was 
placed in the dialysis fluid. 
Dialysis of TF^^ To prepare the material for in vivo use, 
2 ml of leucocyte lysate was dialyzed for 18 hours at 4 C against 200 
volumes of sterile d'iitilled water. The dialysate was shell frozen 
in a dry ice-alcohol bath and lyophilized. The lyophilizate was 
reconstituted in 3.3 ml of sterile distilled water (1 ml for each 
3 X 10^ spleen cells), filter-sterilized (0.22 ym millipore filter) 
and frozen at-20 C until used. 
Dialysis of TF^^ To prepare the material for in vitro use, 
2 ml of leucocyte lysate was dialyzed for 18 hours at 4 C against 
16.6 ml of RPMI 1640 medium (1 ml medium for every 6 x 10^ spleen cells) 
without serum. The dialysate was fil ter-sterilized (0.22 ym Millipore 
filter) and stored at 4 C until used. 
Sigma Chemical Co., St. Louis, Missouri. 
2 Arthur H. Thomas Co., Philadelphia, Pennsylvania. 
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Part 1. Preliminary Adoptive Immunization Experiments 
Utilizing Antigen Stimulated TF Preparations 
A profile of TF preparations used in all preliminary experiments 
is found in Table 4. 
Transfer factor treatments in mice 
A diagram of the treatment schedules of mice with TF is seen 
in Table 5. 
Trial A: Homologous and heterologous treatment Transfer factor 
preparations A (mouse origin) and C (hamster origin) were used to treat 
2 groups of 30 mice each. Each group of mice was given TF 2 days 
pre-challenge and 3 and6 days post-challenge with CVS-27 rabies virus. 
A third group of 30 mice was untreated and served as a control. 
Tenfold dilutions of a 20% (W/V) suspension of rabid mouse brain 
(10^'^ to 10^'^ MICLD50) were made in M-199 cell culture medium. The 
mouse brain suspensions were then titrated in each group of mice by 
IM inoculation of 0.05 ml into the left hind leg. Five mice in each 
group received each dilution. 
Trial B: Homologous TF administered by different routes Transfer 
factor preparation A of mouse origin was used to treat 2 groups of 
30 mice each and a third group of 15 mice. The 30 mice in group 1 
were inoculated per os with the use of a feeding needle. The second 
group of 30 mice was inoculated IP and the third group of 15 mice was 
Table 4. Profile of TF preparations from cell culture supernatant 
Preparation Animal 
Species 
Immun• 
vi rus 
Days PI Cells 
Harvested 
Column. 
Bed 
Protein 
Cone. 
A Mouse MLV-HEP 12 G-25 47 yg/ml 
B Rat CVS-27 7 G-50 113 yg/ml 
C Hamster CVS-27 7 G-25 37 yg/ml 
D Guinea pig MLV-HEP 10 G-25 44 ug/ml 
E Guinea pig MLV-HEP 10 G-25 94 yg/ml 
F Hamster CVS-27 7 G-50 60 ug/ml 
G Skunk CVS-27 7 G-10 + G-25 77 yg/ml 
H Skunk CVS-27 7 G-10 + G-25 115 yg/ml 
a O 
10 cells were cultured for 72 hr in the presence of rabies antigen (SAD). 
^Sephadex gels. 
Table 5. Transfer factor treatment and inoculation regimes used in adoptive transfer 
studies in mice 
Inoculation Dose Inoculation Schedule 
Experiment TF pg Protein 
Preparation per inoculation 
Volume 
1 
Inoculation 
Route 
Days 
Pre-challenge 
Days Group 
Post-challenge Number 
A 
A 2.35 
1.41 
0.05 ml 
0.03 ml 
IM i m i f  
m (RHL) 
2 
3, 6 1 
A C 1.85 1.11 
0.05 ml 
0.03 ml 
IM (RHL) 
IM (RHL) 
2 
3, 6 2 
B 
A 
A 
A 
2.35 
2.35 
2.35 
0.05 ml 
0.05 ml 
0.05 ml 
Per OS 
IP 
IM (RHL) 
3 
3 
3 
1 
2 
3 
C B 3.39 0.03 ml 0.03 ml 
Per OS 
Per OS 
3 
2,4,6,8,10, 
12,14 
1 
C B 3.39 0.03 ml 
0.03 ml 
IP 
IP 
3 
2,4,6,8,10, 
12,14 
2 
C B 3.39 0.03 ml 0.03 ml 
IM (RHL) 
IM (RHL) 
3 
2,4,6,8,10, 
12,14 
3 
A 
D A 
A 
1.41 
1.41 
1.41 
1.41 
0.03 ml 
0.03 ml 
0.03 ml 
0.03 ml 
IM (RHL) 
IC 
IM (RHL) 
IM (RHL) 2 
1 
2 
3 
F 1.8 0.03 IP 3,1 1,3,5,7,9, 1 
E 11,13 
F 1.8 0.03 IP 14,12,10, 3 
8,6,4,2 
a 
RHL - right hind leg, 
^Inoculation of TF immediately preceded the inoculation of challenge viruSi 
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inoculated IM into the RHL. A control group of 30 mice was untreated. 
All test mice were treated 3 days prior to being challenged with CVS-27 
rabies virus. 
Tenfold dilutions of a 20% (W/V) suspension of rabid hamster 
brain (10®*^ through 10^'^ MICLD50) were made in M-199 culture medium. 
The challenge virus was titrated in each group of mice by IM inocula­
tion (0.05 ml) of a dilution of the brain suspension. Mice in the 
third (IM) treatment group were inoculated with only the 3 highest 
dilutions of the virus. 
Trial C: Intramuscular, intraperitoneal and oral treatment with 
TF given pre- and post-challenge with rabies virus Transfer factor 
preparation B of rat origin was administered to 3 test groups of 18 
mice each. A fourth group of 18 control mice was untreated. Groups 
number 1 (per os), number 2 (IP), and number 3 (IM) were treated with 
TF 3 days pre-challenge and on alternate days from day 2 through day 
14 post-challenge with CVS-17 rabies virus. 
Six tenfold dilutions of a 20% (W/V) suspension of rabid mouse 
brain (10^"® to 10^'® MICLD50) were made in M-199 cell culture medium. 
The dilutions of mouse brain suspension were titrated in each of the 
4 groups of mice by IM inoculation of 0.05 ml into the LHL. Each 
dilution of virus suspension was inoculated into 3 mice in each test 
or control group. 
Trial D: Transfer factor treatment intracerebrally and at the 
site of virus challenge Transfer factor preparation A of mouse 
origin was administered to 3 test groups of 18 mice each. Group 
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number 1 was inoculated IC, groups numbers 2 and 3 were inoculated IM 
in the RHL. A fourth group of control mice was untreated. 
Five twofold dilutions of a 20% (W/V) suspension of rabid mouse 
brain (lo/'^ to 10^"^ MICLD50) were made in M-199 culture medium. 
Immediately following the inoculation of TF the mouse brain suspensions 
were titrated in each group of test and control mice by IM inoculation 
of 0.05 ml into the RHL. Each dilution of challenge virus suspension 
was inoculated into 3 mice in each group. Two days post-challenge 
test group number 3 was given a second TF treatment at the site of 
viral challenge. 
Trial E: Enhancement of vaccine response with treatment with TF 
Transfer factor preparation F of hamster origin was used to test if 
the protection afforded mice with the administration of commercial 
rabies vaccine (DEV) could be enhanced with the administration of TF 
from rabid hamsters. 
Four groups of 18 mice each were utilized. Group number 1 received 
TF 3 and 1 days pre-challenge and every other day from day 1 through 
day 13 post-challenge. Group number 2 was inoculated IP every second 
day with 0.25 ml of a 1:10 dilution of a single dose vial of DEV from 
day 13 through day 1 pre-challenge. Group number 3 was treated with 
rabies vaccine in the same manner as group number 2, except that each 
inoculation of vaccine was preceded by 24 hr with an IP inoculation 
of TF. Group number 4 was untreated and served as a control. The 
mice were inoculated IM in the RHL with 0.05 ml. Rabid mouse brain 
was titrated in each of the 4 groups of mice. Five twofold dilutions 
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were made in M-199 culture medium from a 20% (W/V) suspension of brain 
(ic/'^ to 10^'^ MICLD50) and 3 mice in each group received each 
dilution. 
Transfer factor treatment in guinea pigs 
A diagram of the TF treatments of guinea pigs is seen in Table 6. 
Trial A: Treatment with homologous TF Two adult guinea pigs 
were inoculated IM into the left hind leg with TF preparation of guinea 
pig origin 48 hr prior to IM challenge with a 20% (W/V) suspension 
of CVS-27 rabies virus (10^'^ MICLD50) of mouse origin. Challenge virus 
was inoculated IM into the RHL of the 2 TF treated guinea pigs and 
2 untreated controls. 
The brains and salivary glands of guinea pigs which died during 
the course of the experiment were removed for examination using the 
rabies FA test. Impression smears were made from the hippocampus, 
cerebral cortex,  and stem areas of the brain and from a cross section 
of the salivary gland. 
Trial B: Treatment with homologous and heterologous TF factor 
Four adult guinea pigs were inoculated IM into the LHL with TF prepara­
tion D of guinea pig origin and 4 adult guinea pigs were inoculated 
IM into the LHL with TF preparation C of hamster origin. Two untreated 
guinea pigs served as controls. A 1:2 dilution of challenge virus was 
made in M-199 culture medium. Three days after TF treatment 2 guinea pigs 
from each treatment group and one control were inoculated IM into the RHL 
with the 10^"^ MICLD50 challenge virus and the remaining animals were 
inoculated similarly with 10^'^ MICLD50 of the virus. 
Table 6. Transfer factor treatment of guinea pigs 
Inoculation Dose Inoculation Schedule 
Experiment TF wg Protein Volume Inoculation Days Days Group 
Preparation per Inoc. Route Pre-challenge Post-challenge Number 
A D 22 0.5 ml IM LHL* 3 0 1 
D 8.8 0.2 ml IM LHL 3 0 1 
C 18.5 0.4 ml IM LHL 3 0 2 
®LHL = left hind leg. 
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Transfer factor treatments in raccoons and skunks 
A diagram of the TF treatments of raccoons and skunks is seen in 
Table 7. 
Trial A: Treatment of raccoons with heterologous TF One raccoon 
was inoculated IM with TF preparation D of guinea pig origin, another 
with TF preparation E of guinea pig origin. A third raccoon was untreated 
and served as a control. Forty-eight hr after treatment, the 3 raccoons 
were inoculated with 10^*^ MICLD50 of CVS-27 rabies virus in a 20% (W/V) 
mouse brain suspension. 
Impression smears were made of the hippocampus, cerebral cortex, and 
stem areas of the brain and from a cross-section of the salivary gland 
of animals dying during the course of the trial or at the termination of 
the experiment. These smears were examined with FA for confirmatory 
diagnosis of rabies. 
Trial B: Treatment of striped skunks with homologous TF Twelve 
adult striped skunks were arbitrarily assigned to 3 treatment groups of 
4 skunks each. Group number 1 was inoculated with TF preparation G of 
skunk origin. Group number 2 was treated with preparation H of skunk 
origin and group number 3 was inoculated with 0.85% sodium chloride 
solution. 
Forty-eight hr after treatment 2 skunks from each treatment group 
and 2 control animals were challenged with 10^'^ MICLD50 CVS-27 rabies 
virus as a 20% (W/V) mouse brain suspension inoculated IM into the LHL. 
The remaining skunks were challenged with a 1:2 dilution of the 20% 
(W/V) suspension inoculum (10®*^ MICLD50). 
Table 7. Transfer factor treatments of wildlife 
Inoculation Dose Inoculation Schedule 
Expt. Species TF g Protein Volume Inoculation Days Days Group 
Preparation per Inoc. Route Pre-challenge Post-challenge Number 
A Raccoon D 44 1 ml IM 2 0 1 
Raccoon E 94 1 ml IM 2 0 2 
B Skunk G 38.5 0.5 ml IM (RHL) 2 0 1 
Skunk H 57.5 0.5 ml IM (RHL) 2 0 2 
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A pre-treatment and a pre-challenge blood sample were obtained by 
cardiac puncture. This blood sample was assayed by the indirect leucocyte 
migration inhibition technique for evidence of an enhanced cellular 
immune response. The blood sample was also examined by the PHA procedure 
for evidence of a humoral immune response to rabies virus. 
The animals were observed for 51 days for evidence of rabies. The 
brains and salivary glands from the animals that died during the course 
of the study and from the animals that were killed at the termination 
of the trial were examined for rabies antigen by FA. 
65 
Part 2: In Vitro and In Vivo Studies Utilizing 
Mouse Leukocyte Dialysates 
In vitro stimulation of naive lymphocytes with IF 
Five tenfold dilutions of TF^^ preparations from both immunized 
and nonimmunized mice were made in RPMI-1640 medium. Spleen cells were 
collected from unstimulated BALB/c mice in the manner described earlier. 
The lymphocytes were isolated and adjusted to 5 x 10^ cells/ml in 
RPMI-1640 medium containing 5% fetal bovine sera (FBS) and antibiotics. 
Ten aliquots of the cell suspension were sedimented by centrifugation 
at 200 X g for 10 min and each cell pellet was resuspended in a dilution 
of the TFg^ preparations. These cell suspensions were then tested using 
the lymphocyte proliferation assay for evidence of enhanced proliferation 
in the presence of rabies antigen. Appropriate medium, virus, and cell 
controls were tested in conjunction with the assay. The cells were 
cultured in the presence of TF^^ for 7 days as suggested by Ascher et al. 
(1974) for in vitro TF lymphocyte stimulation. 
JLD. vitro assay of the in vivo transfer of immunity to rabies virus 
Transfer factor for in vivo use was prepared as described earlier 
from both rabies-immunized and nonimmunized mice. The RNA concentrations 
of the preparations were adjusted to 10 ug/0.4 ml in sterile distilled 
water. 
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Five mice in each of 3 groups were inoculated IP with 0.04 ml of 
TF from either the immunized mice or nonimmunized mice or with an equal 
volume of sterile distilled water. 
Spleen cells were collected from each group of mice 2 days after 
treatment and tested for evidence of specific response to antigen using 
the lymphocyte proliferation assay. 
Effect of varied doses of TF^^ on resistance to rabies viral infection 
Transfer factor from immunized and nonimmunized mice was adjusted 
to concentrations of 0.5 yg, 1.0 yg, and 10 yg of RNA per 0.5 ml in 
sterile distilled water resulting in 2 types of TF^^ at 3 concentrations 
each. Twenty Swiss-Webster mice were inoculated IP with 0.4 ml of 1 
of each of the 6 solutions. In addition, 20 mice were inoculated IP 
with 0.4 ml of sterile distilled water. 
Three tenfold dilutions of a 20% (W/V) CVS-27 rabid mouse brain 
suspension were made in RPMI-1640 medium for titration in each treatment 
and control group of mice. Five mice in each group were inoculated IM 
into the RHL with 0.05 ml of each dilution 2 days post-treatment with 
T^OW" 
Impression smears of the brains of mice which died during the 
21 day observation period were examined by FA to confirm a diagnosis 
of rabies. 
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RESULTS 
Gel Filtration of Antigen-Stimulated Lymphokines 
The chart recordings of the elution patterns of TF batches which 
were partially purified with the use of Sephadex columns are shown in 
Figures 1-6. The fractions collected and used for in vivo adoptive 
immunization trials are indicated. A considerable amount of variation 
in the patterns was noted for preparations from different lymphocyte 
cultures. 
Protein and RNA Concentration of TF Preparations 
The results of the assays for the concentration of protein and RNA, 
performed on the individual TF preparations, are listed in Table 8. 
These data were used to quantitate the dosage of TF used for adoptive 
stimulation both in vivo and in vitro. 
Lymphocyte Proliferation Assay: Mitogen and 
Antigen Stimulation of Lymphocytes 
In order to determine that all spleen cell preparations were capable 
of being transformed in vitro, each culture of lymphocytes was stimulated 
with Con-A, The concentration of Con-A used to yield a maximum level 
of stimulation for the conditions of culture used during this study was 
determined (Table 9). High concentrations of Con-A were found to be 
Figure 1. Chart recording of elution pattern of cell culture 
supernatant from a Sephadex G-25 column of mouse lymphocytes 
stimulated with MLV-HEP rabies virus and harvested 12 days 
after inoculation 
Figure 2. Chart recording of elution pattern of cell culture 
supernatant from a Sephadex G-50 column of rat 
lymphocytes stimulated with CVS-27 rabies virus and 
harvested 7 days after inoculation 
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Figure 1 
Preparation 
Figure 2 
Preparation 
B 
Figure 3. Chart recording of elution pattern of cell culture 
supernatant from a Sephadex 6-25 column of hamster 
lymphocytes stimulated with CVS-27 rabies virus and 
harvested 7 days after inoculation 
Figure 4. Chart recording of elution pattern of cell culture 
supernatant from a Sephadex G-25 column of guinea pig 
lymphocytes stimulated with MLV-HEP virus and 
harvested 10 days after inoculation 
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Figure 3 
Preparation 
Figure 4 
Preparations 
Figure 5. 
Figure 6. 
Chart recording of elution pattern of cell culture 
supernatant from a Sephadex G-50 column of hamster 
lymphocytes stimulated with CVS-27 rabies virus and 
harvested 7 days after inoculation 
Chart recording of elution pattern of cell culture 
supernatant from Sephadex G-10 and Sephadex G-25 
columns in series. Peripheral lymphocytes from a 
striped skunk were stimulated with CVS-27 rabies virus 
prior to harvest at 7 days 
Figure 5 
Preparation 
Figure 6 
Preparations 
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Table 8. Protein and RNA concentration of TF preparations 
Purification TF Source of Protein RNA 
Procedure Preparation Lymphocytes Concentration Concentration 
yg/ml uq/ml 
A Mouse Peripheral 47 ND^ 
B Rat Peripheral 113 ND 
c 
o C Hamster Peripheral 37 ND 
-p 
ro 
s-4-) D Guinea Pig Peripheral 44 ND 
U_ E Guinea Pig Peripheral 94 ND 
o F Hamster Peripheral 60 ND 
G Skunk Peripheral 77 ND 
H Skunk Peripheral 115 ND 
(/I I Mouse Spleen 160 54 
U) 
>> (O J Mouse Spleen 80 25 
Q K Mouse Spleen 175 41 
L Mouse Spleen 100 23 
^Lowry Reaction. 
^Orcinol Reaction. 
^ND = Not Done. 
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3 Table 9. H-thymidine incorporation of mouse spleen cell lymphocytes 
and stimulation index after exposure to varying 
concentrations of Con-A 
Con-A Average SI® 
Concentration CMP^ 
ug/ml 
150 5.0 0.01 
15 719.5 1.03 
1.5 3337.6 4.80 
.15 5949.5 8.55 
.015 944.8 1.36 
.0015 519.5 0.85 
.00015 503.3 0.72 
0 695.5 
^Average counts per minute of the stimulated culture. stimulati 
Average counts per minute of the control culture. 
^Total counts per minute minus counts per minute of 
background media culture. 
on 
Index 
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toxic to the cultures. The optimum concentration of Con-A added to each 
cell culture was 0.15 g/ml. 
Spleen cells from mice immunized by foot pad inoculation of DEV 
rabies vaccine were cultured in the presence of tenfold dilutions of 
purified SAD virus to determine the optimum concentration of antigen 
necessary to be able to detect a specific cellular response to rabies 
virus. Control cultures consisted of: 1) Spleen cells from nonimmunized 
mice, used to detect nonspecific stimulation; 2) Con-A, used to promote 
nonspecific stimulation; 3) Spleen cells cultured in the presence of 
3 
medium without antigen, used to determine the amount of H-thymidine 
to be incorporated in unstimulated cells and 4) Medium cultures, made to 
quantitate the amount of background radiation that was attributable 
to the medium. 
As illustrated in Table 10, stimulation of spleen cells from 
immunized mice was directly related to the concentration of antigen 
used. A maximum stimulation was detected in microtiter cell cultures 
3 inoculated with a 1:10 dilution of the purified rabies virus preparation. 
Adoptive Transfer Experimentation in vivo: 
Preliminary Studies 
Mi ce 
Trial A: Homologous and heterloqous treatment Titers of rabies 
3 6 
virus in the 3 groups of mice were 10 ' IMLD50 for the homologous 
2 0 TF treatment group, 10 * IMLD50 for the heterlogous TF treatment group. 
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3 Table 10. H-thymidine incorporation of mouse spleen cell lymphocytes 
and stimulation index after exposure to varying concentrations 
of rabies antigen 
Average CPM ® SI ^ 
Rabies Afttiqen-
Dilution Normal Cells Itmnune Cells Normal Cells Immune Cells 
1:10 616.8 432.6 1.37 1.10 
l:lof 562.2 1707.2 1.25 4.34 
1:10^ 697.1 2673.0 1.55 6.80 
1:10* 562.4 2205.4 1.25 5.61 
1:10^ 558.4 1049.6 1.24 2.67 
1:10® 569.5 750.8 1.26 1.91 
0 450.4 393.3 
®Total counts per minute minus counts per minute of 
background media culture. 
^Average counts per minute of the stimulated culture. _ stimulation 
Ind6x Average counts per minute of the control culture. 
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3 2 
and 10 • IMLD50 for the control group. All mice dying after 
exhibiting clinical signs of rabies died between 6 and 9 days post-
challenge. 
Trial B: Homologous TF administered by different routes 
Titers of rabies virus in 3 of the groups of mice were 10^"^^ MICLD50 
for both those receiving TF either per os or IP and for the 
control animals. A virus titer could not be determined for those 
which received TF by the IM route because the 50% endpoint was found 
3 2 to be below the lowest dilution of virus (10 ' MICLD50) administered 
to the mice. 
Trial C: IM, IP and oral treatment with TF qiyen pre- and post-
4 5 
challenge with rabies virus Control mice inoculated with 10 ' 
MICLD50 of CVS-27 rabies virus died of r^abies. This was the highest 
concentration of viral challenge. None of the mice in the 3 TF 
treatment groups died during the course of the trial. 
Trial D: TF treatment IC and at the site of virus challenge 
Mice died in all treatment groups during this trial. As seen in 
Table 11, deaths in the TF treated groups of mice occurred earlier than they 
did in the control groups. The percent mortality for each treatment 
and control group of mice is indicated in Table 12. Prior to day 9 
post-challenge 17% of the IC treated mice, 22% of the IM x 1 group, 
and 28% of those treated with 2 doses of TF had died of rabies as 
compared with 0% deaths in the untreated control group. Mortality 
rates for mice receiving TF were essentially equal to or greater than 
the mortality rate of control mice. 
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Table 11, Periodicity of mouse mortality following treatment with 
TF and subsequent challenge with rabies virus 
TF 
Treatment 
Challenge 
Virus Dose 
MICLD50 
b 
6 7 10 11 12 13 
IC 
IM X 1® 
IM X 2' 
Control 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
5.9 
5.6 
5.3 
5.0 
4.7 
4.4 
5.9 
5.6 
5.3 
5.0 
4.7 
4.4 
5.9 
5.6 
5.3 
5.0 
4.7 
4.4 
5.9 
5.6 
5.3 
5.0 
4.7 
4.4 
D' 
D 
DD 
D 
D 
D 
DDD 
DD 
D 
D 
D 
D 
D 
D 
D 
D 
DDD 
D 
D 
D 
D 
D 
D 
D 
D 
D 
^3 mice in each treatment and control group were inoculated with 
each challenge virus dilution. 
^No deaths occurred before 6 days. 
= no mouse deaths. 
*^D = mouse died from rabies infection. 
X 1 = Treated with TF at the site of virus inoculation 
immediately preceding challenge. 
^IM X 2 = Treated with TF at the site of virus inoculation 
immediately preceding challenge and 2 days post-challenge. 
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Table 12. Mortality rate of mice treated with TF IC and at the 
site or rabies virus challenge 
Days Post-Challenge 
Treatment^ 6^ 7 8 9 10 11 12 13 
vuiiiu lauive 
Total 
IC 
c 
1/18 0/18 2/18 5/18 0/18 0/18 0/18 0/18 8/18 
(%)  (6) (0) (11) (28) (0) (0) (0) (0) (44) 
IMxl 0/18 0/18 4/18 4/18 2/18 1/18 0/18 0/18 11/18 
(%)  (0) (0) (22) (22) (11) (6) (0) (0) (61) 
IMx2 0/18 0/18 4/18 5/18 1/18 1/18 1/18 1/18 14/18 
{ % )  (6) (0) (22) (28) (6) (6) (6) (6) (78) 
Control 0/18 0/18 0/18 4/18 2/18 1/18 2/18 0/18 9/18 
{ % )  (0) (0) (0) (22) (11) (6) (11) (0) (50) 
= 18 for each treatment group. 
^No mice died prior to 6 days post-challenge. 
^Number of mice dead. 
Number of mice treated and challenged. 
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Trial E: Enhancement of vaccine response following treatment with TF 
Table 13 is an outline of the mortality observed in the various treat­
ment groups of mice and the control group following challenge with 
rabies virus. All mice treated with rabies vaccine plus TF and those 
treated only with rabies vaccine survived challenge. Mortality due 
to rabies was observed in both the control group and the group receiving 
TF only. 
All mice receiving TF died of rabies following challenge with 
10^'^ and 10^'^ MICLD50 of the virus. One of the 3 mice treated with 
TF only and challenged with icf'^, 10^'°, 10^*^ and lO*'^ MICLD50 of 
rabies virus died of rabies. Two of 3 untreated control mice died of 
rabies subsequent to challenge with 10^'^, 10^'^, 10^'^ and 10^'^ 
MICLD50 rabies virus; 1 of 3 control mice died after challenge with 
10^'^ MICLD50 and none died following challenge with 10^'^ MICLD50. 
As observed in the preceding experiment, mice treated with TF had an 
earlier onset of death than did untreated control mice. 
Antibody titers of pooled blood samples collected at the termina­
tion of this trial are listed in Table 14. Rabies antibody was not 
detected in sera from mice that received TF alone or in sera collected 
from untreated control mice. Rabies specific antibody was detected 
in the 2 groups (those administered vaccine plus TF and those given 
vaccine alone) of mice which had been injected with rabies vaccine. 
No significant difference (P .05) in antibody titers was seen in sera 
from the 2 groups of mice. 
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Table 13. Periodicity of mouse mortality following treatment with 
TF and/or rabies vaccine and subsequently challenged 
with rabies virus 
Challenge Days Post-Challenge 
_Wirus Dose —r 
Treatment MICLD50 7 8 9 10 11 12 
lOr's D^ D D 
lOc'S - DDD 
lOr n - - D -
TF only 10^ -, - - D - - -
IcC'a - - D - - -
10 - D - -
: : : : : : 
lOr Q ______ 
Vaccine only 10« -, ______ 
10^*4 - - - - -
10 -
1  O r  r  _ _ _ _ _ _  
lOq': 
lOg'o - - -
TF + Vaccine I0J7 -
10,*4 - - -
10 -
lOr r - - D D - -
lOc'S - - - - D D 
control ]g5:o ] : g ? : Ô 
^3 mice in each treatment and control group were inoculated 
with each challenge virus dilution. 
^No mice died prior to day 7 post-challenge. 
^D = mouse died from rabies infection 
= no mouse deaths. 
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1 
Guinea pigs 
Trial A: Treatment with homologous TF Three of 4 guinea 
pigs died by 8 days post-challenge. These 3 included both control 
animals and 1 guinea pig treated with TF. As seen in Table 15, 
rabies antigen was identified by rabies FA in tissues from all animals 
dying during the course of this trial. The 1 remaining TF-treated 
guinea pig remained healthy for more than 1 year post-challenge. 
Trial B: Treatment with homologous and heterlogous TF A11 
guinea pigs used in this trial died of rabies as determined by clinical 
signs of the disease and rabies FA examination of impression smears 
made from brain tissues. The guinea pigs died within 5 to 7 days after 
challenge with rabies virus. 
Raccoons 
Twenty-seven days post-challenge the control raccoon died of 
rabies as diagnosed from clinical observations and confirmed by rabies 
FA staining of tissue impression smears. Smears of the hippocampus, 
brain stem and cerebral cortex were highly positive for the antigen 
but the salivary gland was found to be negative. No clinical signs 
of rabies were observed in the 2 raccoons receiving TF and both survived 
until termination of the trial at 48 days post-challenge. Impression 
smears of brain and salivary gland tissues were negative for rabies 
antigen as determined by specific FA staining. 
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Table 14. Antibody titer^of pooled^ blood samples 
Challenge virus dose (MICLD50) 
Treatment icf'S 105.6 
CO If
) 
o
 iqS.O lO*'^ lo4'4 
TF ND^ ND Neg Neg Neg Neg 
Vaccine 1:8. 1:16 1:2 1:4 1:2 1:2 
TF + Vaccine 1:4° 1:16 1:8 1:2 1:8 1:8 
Control Neg Neg Neg Neg Neg Neg 
^Antibody titer determined using the rabies PHA test. 
^Pooled sample of blood from mice in each group of 3 challenged 
with rabies virus which survived until the termination of the 
experiment. 
^ND = not done. 
^Neg = no detectable rabies antibody. 
* 
No significant difference in geometric mean titers between mice 
treated with vaccine alone and mice treated with TF plus vaccine 
(P .05). 
Table 15. Results of rabies FA examination of guinea pig brain and 
salivary gland impression smears 
Fluorescence 
TF Died Hipp.® C.C.b B.S.^ S.G.^ 
Treatment Days PC 
Preparation D 8 1+ 1+ Neg Neg 
Preparation D - - -
Control • 8 1+ Neg Neg Neg 
Control 8 3+ 3+ 4+ 1 + 
®Hipp. = hippocampus. 
'^C.C. = cerebral cortex. 
^B. S. = brain stem. 
*^S. G. = salivary gland. 
®PC = post-challenge inoculation. 
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Striped skunks 
The results of TF treatment of skunks are listed in Table 16. 
The two skunks (671 and 667) which had detectable rabies antibody and 4 
animals (182, 675, 669 and 672) which had detectable cellular responses 
in blood samples taken prior to treatment with TF were excluded from 
further consideration in this study. One of 3 remaining animals treated 
with TF preparation G and 1 of 1 remaining skunks treated with TF 
preparation H died of rabies as diagnosed by clinical and rabies FA 
testing. Both of these skunks had been challenged with 10®'^ MICLD50 
rabies virus. None of the 2 remaining control skunks died of rabies. 
Two of 3 (664 and 665) skunks which received TF preparation G 
reverted from a negative to a positive cellular immune response 
C O 
2 days after treatment. These 2 animals were challenged with 10 * 
MICLD50 rabies virus as was the control skunk challenged with this 
dose of virus. 
Adoptive Transfer Experimentation in vitro 
Effects of TF and antigen on unsensitized lymphocytes 
Lymphocyte proliferation assays were performed on normal mouse 
spleen cells cultured in the presence at TF^^ and antigen to determine 
if TF derived from immunized mice could specifically stimulate lymphocytes 
from nonimmunized mice in vitro. As seen in Table 17, no specific or 
nonspecific stimulation of the lymphocytes was noted for nonstimulated 
lymphocytes cultured with antigen from either TF^^ nonimmunized mice 
Table 16. Comparison of pre- and post-treatment humoral and cellular immune responses in skunks 
Treatment TF Preparation G TF Preparation H Control 
Challenge 106'6 MICLD50 lO^'^MICLDSO 106.6 MICLD50 iof'3 MICLD50 106.6 MICLD50 106.3 MICLD50 
Animal 
Number 182® 663 664 665 666 667® 675® 669® 670 671® 672® 673 
PHA^ Neg/ 
ND^ 
1:2/ Neg/ 
1:2 1:2 
Neg/ 
Neg 
Neg/ 
Neg 
1:4/ 
ND 
1:2/ 
ND 
Meg/ 
ND 
Neq/ 
1:2 
1:4/ 
ND 
Neg/ 
ND 
Neg/ 
1:2 
MI^ 0.65+/* 
ND 
1:31/ 1:11/ 
0.99 0.78+ 
0.94/ 
0.67+ 
1.06/ 
1.05 
0.95/ 
ND 
0.71+/ 
ND 
0.56+/ 
ND 
0.83/ 
1.02 
1.05/ 0.55+/ 
ND ND 
0.89/ 
1.32 
FA® ND + Neg Neg + ND ND ND Neg ND ND Neg 
^Eliminated from the study because of positive initial humoral or cellular immune response. 
^PHA = passive hemagglutination; a titer of 1:4 is considered positive. ,day of treatment assay^ 
^day of challenge assay^ 
Sd = not done, y = migration index, :::p 
FA = Rabies specific fluorescent antibody assay of brain impression smears. 
Significantly positive (P .05). 
Table 17. Stimulation indices of normal mouse lymphocytes cultured in the presence of TF-y 
and rabies virus ' 
Virus Dilutions 
Dilutions 1:10 1:10^ 1:10^ 1:10^ 1:10^ 1:10^ 1:10^ 1:10^ 1:10^ Con-A* 
'5 1 
s: •!- 0) o c o 
i- O •!— 
- C E  
10 
10^ 
10" 
10^ 
10 
10 
10^ 
10" 
10^ 
10" 
5 
1.4 1.7 1.6 1.7 1.8 1.6 1.4 1.4 1.0 8.6 
1.0 1.2 1.0 1.3 1.7 1.4 1.3 1.0 1.3 7.1 
1.3 2.1 2.2 2.0 1.4 1.5 1.2 1.1 1.3 10.2 
1.0 1.2 1.2 1.3 1.1 1.4 1.7 1.4 1.4 7.1 
1.5 2.3 1.9 1.8 1.6 1.5 1.0 1.2 1.3 7.8 
2.0 2.3 1.7 2.0 1.8 1.5 2.4 1.6 1.1 10.3 
1.5 2.0 1.3 1.4 1.3 1.5 1.6 1.6 1.4 5.5 
1.6 1.8 1.6 1.6 1.7 1.5 1.5 1.3 0.9 8.7 
1.0 1.5 1.4 1.5 1.2 1.0 1.1 1.0 1.2 7.3 
1.4 1.7 1.3 1.3 1.2 1.3 1.1 1.2 1.0 9.9 
^Con-A concentration = 0.15 uO per culture well. 
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or TFpn^ from immunized mice. 
Adoptive Transfer Experimentation in vivo 
Effect of TF ojx lymphocyte proliferation response 
In order to determine if lysate TF from mice immunized with 
rabies virus could enhance the cellular immune response to rabies virus 
in vivo, inbred mice were treated with TF by IP inoculation with either 
TF or with an equal volume of saline. Transfer factor derived from 
immunized mice TF^^^ and nonimmunized mice (TFp,^_) was used in order 
to identify any nonspecific lymphocyte stimulation or inhibition. 
Table 18 is an outline of the results of the proliferation assays 
performed on the 3 treatment groups of mice. Lymphocytes from mice 
treated with either TF^^^ or TFQ^_ had significantly higher average 
3 incorporation of H-thymidine than did lymphocytes from mice treated 
with an equal volume of saline. In addition, the SI of cells from 
TFg^^ treated mice cultured in the presence of antigen dilutions 
(1:10^ through 1:10^) were significantly (P<.001) higher than those 
observed from the similarly treated culture of cells from TFp^_ and 
saline treated mice. Significance was determined by the Student's 
t-test for unpaired means utilizing the count per minute readings and 
the stimulation indices of the individual replicate cell cultures. 
3 Table 18. H-thymidine incorporation of mouse lymphocytes after in yiyo treatment with 
TF or saline 
Average CPM^ SI's^ 
Anti gen TFoW-d Saline TF+DW TF'DW Saline 
0 12423.8 12267.0 682.4 
1:10 8723.9 2214.2 330.5 0,7 0.2 0.5 
1 ziof 29335.4 6314.4 934.0 
** 
2.4 0.5 1.4 
1:10^ 34491.6 9768.9 928.5 
** 
2.8 0.8 1.4 
1:10^ 33766.1 16128.5 996.5 
** 
Z.7 1.3 1.5 
1:10^ 33165.5 20578.0 862.0 
** 
2.7 1.7 1.3 
1:10^ 18816.9 16127.9 803.4 1.5 1.3 1.2 
1:10^ 12618.6 14430.4 669.6 1.0 1.2 1.0 
1 ;10® 13426.7 15732.6 787.5 1.1 1.3 1.2 
1:10^ 12271.8 8931.2 692.6 1.0 0.7 1.0 
^CPM = Counts per minute minus media background. 
^Average counts per minute of the stimulated cell cultures _ c4.,-„,,i3tir,n ThHpy 
Average counts per minute of the unstimulated cell cultures 
""Transfer factor derived from immunized mice. 
"^Transfer factor derived from nonimmunized mice. 
Significantly higher (P .001) average CRM than CRM for lymphocytes from saline treated mice. 
Significantly higher (P .001) SI than determined for the stimulation of either TF-^^ 
treated or saline treated mice. 
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Effect of TF oil resistance to infection with rabies virus 
Swiss-Webster mice were treated with or TFpj^_ by IP 
inoculation of 10, 1 or 0.5 pg of RNA in 0.4 ml of saline. A control 
group of mice was inoculated with 0.4 ml of saline only. After 2 days 
the mice were challenged with CVS-27 rabies virus inoculated IM irto 
the RHL. As can be seen in Figure 7, there was no protection afforded 
to mice as a result of having been treated with either of the sources 
of TF. All mice which died during the course of this experiment died 
of rabies, as determined with the rabies FA procedure. 
Figure 7. Mortality of TF^^treated mice after challenge with 
CVS-27 rabies virus (N = 5) 
H Treated with TF (RNA) from immunized mice 
n Treated with TF (RNA) from nonimmunized mice 
K3 Treated with saline 
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DISCUSSION 
The transfer of lymphocytes or extracts of lymphocytes from 
sensitized donors to naive recipients has been used in man and other 
mammals to transfer immunity adoptively against a wide variety of 
pathogens. In early studies of the association of cellular immunity 
with rabies viral infections. Turner (1973) was unable to demonstrate 
any protection from rabies in mice which had been injected with 
splenocytes from syngeneic, immunized mice. More recently, however, 
Prabhackar, cited by Shope et al. (1979), was successful in transferrinn 
the resistance. Lagrange et al. (1978), using the foot pad test, 
showed that an in vivo CMI occurred in mice after adoptive immunization 
with sensitized splenocytes. Wiktor et al. (1974) and Hill (1974) 
observed in vitro lymphocyte blastogenesis in rabies-stimulated cell 
cultures from immunized rabbits and mice,respectively. Wiktor et al. 
(1974) and Wiktor et al. (1977a) also successfully demonstrated cell-
mediated cytotoxicity using immune lymphocytes from mice and rabbits 
in a chromium release assay. 
All published reports of adoptive transfer of immunity to rabies 
virus have involved the use of whole cells inoculated into syngeneic 
mice. In addition, in vitro demonstrations of cellular immunity have 
involved the stimulation of viable lymphocytes obtained from immunized 
animals. Although the occurrence of protection from rabies viral 
infection after the adoptive transfer of splenocytes is an interesting 
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phenomenon, the practical application of this technique is extremely 
limited due to the immunorejection reactions in other than syngeneic 
systems. 
Theoretically, with the use of the dialyzable leucocyte extract» TF 
animals could be adoptively immunized against rabies and thus bypass prob-
blems associated with immunorejection. Also, because the use of TF is not 
limited by allotypic barriers, it could be stimulated in domestic animals, 
for general use. A third major advantage of the use of TF is that adop­
tive transfer of immunity would not require immunization with the virus. 
The purpose of this study has been to test the efficacy of TF 
preparations for immunization of laboratory and wildlife animal species. 
The activity of TF was also tested in vitro using the lymphocyte 
proliferation assay. The TF preparations were partially purified either 
by dialysis or with the use of gel filtration through Sephadex G-25 
or G-50. Two columns, 1 containing Sephadex G-10 and the second G-25, 
were run in series to purify TF preparations G and H (Table 4). 
Because Lawrence et al. (1963) found that the fraction collected at 
peak 2, after filtration through Sephadex G-25, was able to transfer 
coccidioidin sensitively whereas the peak 1 components failed, the 
second component eluted in gel filtration also was selected for use 
in these experiments. 
Dialysis is widely used today for purification of TF. The 
techniques described by Ascher et al. (1974) and Salaman (1978) were 
used as a model for this means of purification of some TF preparations. 
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In preliminary studies, a low level of resistance to challenge with 
rabies virus was seen in mice treated with heterologous TF of hamster 
origin in Trial A. The protection observed after pre- and post­
exposure treatment with a total of 4.07 y g of preparation C was only 
15.8 IMLD50 above the resistance seen in untreated control mice and 
can not be considered significant. Mice treated with homologous TF 
had a slightly higher mortality rate than was observed in the untreated 
control group but this increased susceptibility also is insignificant 
and possibly due to biological variation among the individual animals. 
It should be noted that mice receiving homologous TF received a 
greater protein concentration than did mice which were treated with the 
heterologous preparation. Using the skin test response to tuberculin, 
Welch et al. (1976) observed a reduction in the number of responding 
animals after increased dosages of TF were administered, but Vandenbark, 
et al. (1976),using the same test system, were unable to induce any 
reduced skin test response after the administration of as much as 10 
times the minimum level of TF needed to transfer reactivity to tuberculin. 
It was decided to repeat Trial A, using homologous TF preparation A at a 
lower dosage level. The added dimension of various routes of TF ad­
ministration also was incorporated into Trial B. Lawrence (1974) reported 
that IV, IP, and IM routes of administration were equally effective when 
used to immunize guinea pigs adoptively against tuberculin and Jeter et al. 
(1977) reported the successful transfer of sensitivity to tuberculin in 
human recipients after TF administration per os. 
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The infectivity of the challenge virus, inoculated IM, was lower 
than was expected and deaths of mice in both groups were insufficient 
for a valid test of the relative resistance of treated and control 
mice. For this reason, the experiment was repeated with the use of a 
different batch of TF and a different batch of rabies virus inoculum. 
Trial C involved mice that received TF both pre- and post-challenge 
with rabies virus. As in Trial B, the infectivity of the challenge virus 
inoculated IM was lower than was expected. However, control mice 
challenged with lo'^*^ LD50 of CVS-27 rabies virus died of rabies and 
all treated mice were resistant to rabies at this level of challenge. 
None of the treated or control mice died of rabies after challenge with 
higher dilutions of the virus inoculum. 
If the use of TF was found to be an efficacious immunizing agent 
against rabies in wild animal species, oral inoculation of wild populations 
with TF incorporated in food baits may be an efficient method of adoptive 
immunization. Because 9 of 9 treated mice survived while 3 of 3 untreated 
mice died when challenged IM with 10 * LD50 of the virus inoculum, 
it appears that TF treatments may have resulted in some increased resistance 
to infection with rabies virus. 
It is believed to be desirable to develop a means of immunizing 
wildlife against rabies because the disease is endemic in populations 
of sylvatic animals in the United States, with occasional spill over 
into populations of domestic animals and humans. Investigations into 
the feasibility of using TF adoptively to immunize wildlife involved 
the use of raccoons and striped skunks, both of which pose significant 
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public health problems due to rabies in this country. 
In the first such trial, 2 raccoons were treated with different 
TF obtained from the same guinea pig lymphoid cell culture supernate. 
A third raccoon was untreated and served as a control. At 48 hrs 
5 "3 post-treatment, all 3 raccoons were inoculated IM with 10 ' MICLD50 
of rabies street virus of skunk origin. The control raccoon died of 
rabies 27 days post-challenge and rabies was later confirmed by FA 
testing of brain tissue impression smears. The 2 treatment raccoons 
survived until termination of the experiment 48 days post-challenge. 
No clinical signs of rabies were observed and FA staining of brain 
tissue impression smears did not indicate any rabies antigen was present. 
This study lacks the necessary monitoring and controls to state 
definitely that the raccoons were protected by the adoptive transfer 
5 1 
of CMI; however, the challenge virus dose of 10 ' MICLD50 is considered 
to be sufficiently high to give 100% mortality to the raccoons on test. 
Sikes and Tierkel (1960) found a 70% mortality rate in raccoons inoculated 
4 2 IM with 10 ' MICLD50 of rabies virus of fox salivary gland origin, and 
McLean in 1975 (describing the unpublished data of Sanderson) reported 
a 66% mortality rate in raccoons inoculated with 10^'^ MICLD50 of rabies 
virus of skunk origin. 
There is a remote possibility that sufficient time had not been 
allowed for the disease to manifest itself in the 2 surviving raccoons. 
In the Sikes and Tierkel (1960) and the Sanderson (McLean 1975) studies, 
incubation periods in raccoons challenged with 10^'^ to 10^'^ MICLD50 
of rabies virus ranged from 13 to 35 days. However, 1 raccoon inoculated 
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with 10 • MICLD50 of rabies virus in the Sanderson study survived 
for 107 days post-inoculation. This raccoon died of rabies but only 
5 days after having been administered 12 daily injections of 10 mg of 
cortisone acetate. 
It has been suggested that leucocyte inhibition assays can be used 
to detect TF activity in vitro (Wilson et al. 1979a,b and Borkowsky 
and Lawrence 1979a,b). Levin et al. (1970) reported induction of migration 
inhibition factor after injection of TF into patients with Wiskott-
Aldrich syndrome and Goust et al. (1976) reported the induction of 
leucocyte migration inhibition factor after injection of TF into 
patients with measles. In Trial B of the wildlife studies, in which 
TF was administered to striped skunks, the ILMI assay was used to 
determine if an increased cellular inactivity could be detected in vitro 
2 days after treatment. As indicated in Table 16, 2 of 3 skunks treated 
with TF preparation G became sensitized to rabies virus. This would 
suggest that the TF treatment did specifically stimulate skunk 
lymphocytes. 
The lymphocytes from the 1 skunk treated with TF preparation H 
apparently were not sensitized to rabies antigen and did not produce 
migration inhibition factor detectable in the in vitro test. Lymphocytes 
collected from control animals also remained negative for migration 
inhibition factor. 
None of the skunks inoculated IM with 10^"^ MICLD50 died of rabies 
but rather all remained healthy until they were killed at the termination 
of the experiment. However, 1 skunk (663) treated with TF preparation 
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G and 1 skunk (666) treated with TF preparation H died of rabies after 
challenge with 10^'^ MICLD50 CVS-27 rabies virus. Neither of these 
animals had a detectable cellular immune response prior to challenge. 
Although these findings may suggest that a rabies specific cellular 
response indicates protection from rabies infection, control animals 
which did not have detectable cellular responses also survived 
challenged with the virus. Alternative mechanisms of resistance may 
have influenced the protection observed. A very high intestinal 
parasite load was noted at necropsy of the 1 surviving control skunk 
challenged with the higher concentration of virus. Although parasites 
were observed in some other animals, the level of infection was much 
lower. Helminths have been shown to potentiate the immune response 
to unrelated antigens nonspecifically (Welch 1976). 
The dose of challenge virus inoculum should have been sufficient 
to give 100% mortality in nonimmune animals. Sikes and Tierkel (1960) 
c 1 
reported that a challenge dose of 10 ' MICLD50 rabies street virus 
resulted in 100% mortality in striped skunks. The skunks in this study 
were inoculated with a laboratory strain of the virus (CVS-27) which had 
been propagated in mice for 5 passages. It is possible that the virulence 
of the virus was lower for the skunks than it was for mice. This 
phenomenon has since been observed in this laboratory during other 
studies with skunks that were inoculated with CVS-27 rabies virus 
propagated in mouse brain. 
It is well-documented that TF does not augment the antibody production 
(Lawrence 1974), and it has been proposed that its activity is restricted 
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to a subpopulation of cytotoxic T-cells (Basten et al. 1975). 
Theoretically, treatment with both vaccine (to stimulate the humoral 
and cellular response) and TF (to stimulate the cellular response) 
could have an additive effect. Assuming that this would be better than 
immunization with either vaccine or TF alone, a higher survival rate 
would be expected in mice treated with both agents. This theory was 
tested in mice with inconclusive results. The 2 groups of mice treated 
with vaccine had a higher survival rate than did those treated with 
TF alone or the untreated controls. Since all mice treated with vaccine 
alone or with vaccine plus TF survived challenge with rabies virus, no 
distinction could be detected between the vaccinated groups. At the 
termination of the study, antibody was detected in both vaccine-treated 
groups of mice but not in the TF-treated mice nor in the untreated 
controls. No significant differences in antibody titers were seen between 
the 2 vaccinated groups of mice, supporting the thesis that TF has no 
direct effect on the stimulation of the humoral immune system. Since 
antibody was tested at 21 days post-challenge with rabies virus, it is 
conceivable that, by this time, some mice treated with TF alone or 
untreated mice could also have seroconverted. However, for unknown reasons, 
no antibody was detected in sera from these groups of mice. 
Recent in vitro (Wiktor et al. 1974, Hill 1974 and Wiktor et al. 
1977a,b) and in vivo (Lagrange et al. 1978, Shope et al. 1979 and Tsiang 
and Lagrange 1980) studies have indicated that the cellular immune 
response contributes to an animal's ability to resist viral infections. 
Wiktor et al. (1977b), using the chromium release assay, suggested that 
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the level of resistance is directly correlated with the level of cytotoxic 
T-cell response and Miller et al. (1978) reported that CMI was involved 
in the clearance of rabies virus from the CNS. Other studies have also 
suggested that the cellular immune response has a vital role in the 
development of the pathologic conditions responsible for death following 
rabies infections. Iwasaki et al. (1977) found that nude mice (a highly 
inbred strain of mice characterized by a lack of T-cell function) ex­
perienced a significantly longer mean survival time (14.0 days) than did 
immunocompetent mice (mean survival time 12.0 days) after experimental 
infection with rabies virus. 
In mouse trials D and E described in this dissertation, treatment 
of mice with TF resulted in a reduced resistance to challenge with 
rabies virus. Treated mice in both trials not only had a higher mortality 
ratio than did untreated control mice, but also exhibited a shorter 
incubation period for the infection and a shorter duration of morbidity. 
These observations appear to be in direct conflict with the previously 
described positive results of adoptive immunization of mice, a guinea 
pig and the raccoons. However, many variables exist in the preliminary 
studies, including: 1) the source of the immunizing virus, 2) the species 
of animal immunized for preparation of TF, 3) the purification procedure 
for the TF preparations, 4) the dose of TF administered, 5) the species 
of animal adoptively immunized, 6) the route of administration of TF, 
7) the schedule of immunization, and 8) the source of challenge virus. 
Any 1 or combination of the above variables may have influenced the 
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observed results. However, many of the studies did indicate that the 
activity of TF may regulate the ability of an animal to resist rabies 
viral infection. 
Although the preliminary studies were designed to develop adoptive 
immunization techniques and to give an indication of the feasibility 
of using TF to immunize animals against rabies virus, the follow up 
series of experiments was designed to minimize the variability described 
above, to quantitate more effectively the adoptive immunization pro­
cedures, and to measure the results more accurately. These experiments 
were performed in vivo with the use of both inbred and outbred mice 
and jjx vitro with the use of mouse splenocytes. The i_n vitro and in 
vivo studies were performed with TF preparations from the same spleen 
cell populations, and both the in vitro and in vivo TF activities were 
monitored using the lymphocyte proliferation assay. The dosage of TF 
used in these studies was defined by the amount of RNA contained in the 
TF preparation as determined by the orcinol reaction. 
Ascher et al. (1974) described studies with TF prepared by dialysis 
in which he was able to demonstrate the adoptive transfer of immunity 
to tuberculin, streptokinase-streptodolnase, diphtheria toxoid, and 
coccidioidin in vivo from human donors to human recipients and in vitro 
from immune lymphocytes to nonimmune lymphocytes. They reported that 
TF prepared by the conventional technique of dialysis of leucocyte 
extracts against distilled water was not satisfactory for in vitro use, 
but, when the leucocyte extracts were dialyzed against tissue culture 
medium, the activity of the TF for in vitro use was enhanced and could 
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be measured iji vitro. 
In an attempt to demonstrate rabies-specific activity of TF 
in vitro, spleen cells from nonimmune mice were cultured in the 
presence of various dilutions of antigen and various concentrations 
of TF derived from both immunized and nonimmunized mice. As seen in 
Table 17, no specific or nonspecific stimulation of the normal 
lymphocytes was detected. Stimulation of the same cell populations 
with Con-A indicated that the cells were capable of undergoing 
transformation. 
In the Ascher et al. (1974) study, time-course experiments 
indicated that 7-day cell cultures were necessary to demonstrate maximal 
differences in cell proliferation caused by TF^^. Hill (1974) reported 
a maximum proliferative response of mouse lymphocytes cultured in the 
presence of antigen for 4 days and a sharp fivefold reduction of the 
stimulation index by day 6. It is possible that the 7-day culture 
recommended by Ascher et al. (1974) for the stimulation of naive 
lymphocytes by TF in vitro and the recommended 4 day incubation period 
for rabies antigen stimulation of sensitive lymphocytes were mutually 
exclusive. As a result no stimulation was detectable. It is also 
possible that no adoptive transfer of immunity had occurred. 
Salaman (1978), in a study designed to repeat the Ascher et al. (1974) 
study, also was unable to demonstrate any antigen-specific transfer 
of sensitivity to normal lymphocytes in vitro. 
When spleen cell lymphocytes from mice which had been inoculated 
with either TF^^^ or TFQ^_ 2 days prior to harvest were cultured 
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without antigen, a significantly (P<.001) higher level of background 
stimulation was observed. Salaman (1978) described a similar background 
stimulation when lymphocytes from tuberculin negative persons were 
cultured in the presence of TF also derived from tuberculin negative 
donors. However, in the in vitro system of Salaman, no antigen-
specific proliferation was detected above the background nonspecific 
stimulation. 
The results outlined in Table 18 indicate that significantly higher 
(P<.001) stimulation indices were noted in lymphocyte cultures from 
mice which had been inoculated with TF from rabies positive mice and 
cultured in the presence of rabies antigen than was noted in lymphocytes 
from mice which had been administered either TFp^_ or saline. These 
data strongly suggest that the TF^y^ was capable of specifically 
transferring sensitivity to rabies virus in vivo. 
No correlation between the specific and nonspecific stimulation 
of lymphocytes and resistance to rabies infection was observed. Figure 
7 indicated that mice treated with various dosages of TF^^^, TFQ^_, 
or a saline placebo all had similar mortality patterns after challenge 
with CVS-27 rabies virus. In addition, the mortality and the onset 
of morbidity were similar in all treatment and control groups of mice, 
in contrast to the observations noted earlier where treatment with 
column-purified TF appeared to result in shorter incubation periods 
and earlier mortality for the nice. 
No definitive conclusions can be drawn as to the efficacy of TF 
as an immunizing agent against rabies virus. Mortality data were 
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highly variable, however, it did appear that treatment with TF may have 
been an influence in the resistance to infection exhibited by some 
mice, a guinea pig, raccoons and some skunks. Resistance from rabies 
also appeared to have been inhibited in 2 of the trials done in mice 
and no effect was noted in other mouse trials. 
Evidence of specific stimulation of CMI with TF used in vivo was 
demonstrated both in skunks and in mice using in vitro assays. However, 
data indicating a correlation between resistance to challenge are lackinq 
and only questionable in the trial utilizing skunks. A high nonspecific 
stimulation of lymphocyte proliferation was observed when mice were 
treated with either TF^^^ or TFp^_. Finally TF^^ did not, either 
specifically or nonspecifically, stimulate naive lymphocytes in vitro. 
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APPENDIX 
Raccoon, Fox, Bat, and Skunk Rabies in the United States 
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Raccoon rabies 
Raccoons are broadly distributed in the continental United States 
with the exception of isolated areas in the high mountain and desert 
regions of the West (Schwartz and Schwartz 1959). Rabies in this 
species occurred infrequently in most areas but was endemic in Georgia, 
Florida, Alabama and South Carolina (Scatterday et al. 1960, Irvin 
1970, Prather et al. 1975 and CDC 1980g). In 1979, 93% of 543 cases 
of raccoon rabies found in the United States were reported from these 
four states. 
Sikes and Tierkel (1960) found raccoons to be approximately 1000 
times more resistant to rabies of fox salivary gland origin than were 
striped skunks. They observed comparatively shorter incubation periods 
and longer morbidity periods in raccoons than in foxes and in skunks. 
McLean (1975), reporting unpublished data of G. C. Sanderson, identified 
a somewhat longer incubation period (ranging from 18 to 66 days) in 
raccoons inoculated with rabies virus isolated from raccoon salivary 
glands than the 10 to 42 days incubation period seen in the raccoon 
of the Sikes and Tierkel (1960) study. One unusually long incubation 
period was observed in a raccoon (in the Sanderson study) which died 
of rabies 107 days after inoculation with the virus and 3 days after 
the completion of 12 daily injections of 10 mg of cortisone acetate. 
No clinical signs of rabies were observed prior to the initiation of 
cortisone treatments. Bigler et al. (1973) reported 2 naturally infected 
raccoons died of rabies 30 and 70 days after capture. Since the time 
and the source of exposure cound not be determined, these suggested 
a minimum incubation period. 
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Scatterday et al. (1960) described the behavior of 38 naturally 
infected rabid raccoons in Florida as totally unaggressive. No un­
provoked attacks were reported. Similar observations were made after 
another Florida study by Kappus et al. (1970) who identified only 1 of 
31 rabid faccoons as frankly aggressive. Sick or peculiar behavior 
was the most frequently reported characteristic. 
However, more recent studies have indicated that aggressive 
behavior is not uncommon in rabid raccoons. Of 570 rabid raccoons in 
Georgia, 47% were reported as showing aggressive behavior: 39% were 
found within yards during daylight; 34% were fighting with dogs; 
13% showed no fear when attacking human beings; 7% were walking with 
an irregular gait; and 6% were killed or found dead on the road 
(McLean 1975, reporting unpublished data of Dreesen and Burnham). 
McLean (1975) further claimed that 46% of rabid raccoons from Florida 
and Georgia displayed some sort of aggressive behavior. 
McLean (1975) suggested that raccoons pose a greater threat for 
human exposure than do other wildlife species. Raccoons readily adapt 
to life in urban situations where they not only are tolerated, but often 
are treated as semi-domestic pets (Bigler et al. 1973). They often 
bite or scratch people who, thinking they are tame, approach them 
(McLean 1971). Furthermore, a relatively large proportion of raccoons 
may become infected in epidemics. During a rabies epidemic in Florida, 
Kappus et al. (1970) found that 10% of nonrabies-suspect raccoons were 
positive for the virus both in their saliva and in their brain tissues. 
The potential hazard of exposure to rabies by raccoons kept as 
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pets was emphasized recently in Florida (CDC 1980c). Public health 
officials determined that at least 150 people had been exposed to a 
rabid pet raccoon. Rabies post-exposure prophylaxis at an estimated minimal 
cost of over $20,000 was recommended for 74 of those exposed. 
Fox rabi es 
Rabies in foxes in the United States has been recognized for more 
than 200 years. The disease apparently was introduced into this country 
by imported dogs from which it spread to foxes (Steele 1975). The 
first major epidemic was reported by Thatcher in 1812 in Massachusetts 
(Gier 1948). Since that time epidemics of fox rabies have occurred 
primarily east of the Mississippi River (Wilkison 1893-94, Guilford 1938, 
Schoeninq 1942, Comoton 1943, Garlouqh 1945, Johnson 1945, Wood 1954, 
Parker et al. 1957, Friend 1968 and Sikes 1975). 
Three species of foxes are of primary importance in the epidemiology 
of sylvatic rabies in the United States. The red fox (Vulpes vulpes) 
is broadly distributed from the Arctic to south Texas with the exception 
of the extreme southeast and the arid regions of the middle and far 
west. The gray fox (Urocyon cinereoargenteus) occurs in broad areas of 
the 48 contiguous states. It is not found in much of the northern 
2 tiers of states from Washington to North Dakota or in western 
Nebraska and Kansas. A third species, the Arctic fox (Alopex lagopus), 
is restricted in its distribution to the tundra zone of northern and 
western Alaskan islands in the Bering Sea and has been introduced onto 
many of the Aleutian Islands (Rausch 1958). 
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Generally, in reports of the incidence of fox rabies in the 
United States, no distinction is made among the various species of 
foxes. However, from isolated surveys, it can be seen that red fox 
rabies is most prevalent in the northeast, whereas gray fox rabies is 
epidemiologically important in southeastern states (Sikes 1975). 
Parker et al. (1957), Friend (1968) and Schnurrenberger et al. (1970b) 
have reported that during epidemics of fox rabies the ratio between 
reported cases in the 2 species was approximately equal to the ratio of 
their population size as determined from trapping records. No signif­
icant difference between red and gray foxes in the prevalence of rabies 
was reported by Davis and Wood (1959) in Georgia, Florida, and South 
Carolina. Rausch (1958) made a similar observation when discussing the 
disease in relation to the species distribution of Arctic and red foxes 
in Alaska. 
Nationally, reported cases of rabies in foxes have declined in 
the 25 year period between 1953 and 1977 from over 1000 cases in 1953 
to 122 cases in 1977. Whereas foxes represented 70% of all sylvatic 
rabies reported in 1953, they accounted for only 3% in 1979 (CDC 1978b 
and 1980a). In 1979, only Maine and Alaska reported more cases of 
rabies in foxes than in any other species (CDC 1980a). 
Foxes are highly susceptible to rabies viral infection (Sikes 
1962). Although incubation periods of as long as 13 months have been 
reported for rabies in foxes (Steele 1967), this is probably not usual. 
Sikes (1962) reported that the disease seen in foxes inoculated with 
O 
what is considered to be a large inoculum of virus (10 MICLD50) 
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had a short incubation period (less than 18 days); smaller inocula 
3 
resulted in incubation periods of 38 days or more. Titers of 10 
MICLD50 virus or greater were seen in the salivary gland of foxes with 
clinical disease appearing after long incubation periods. Based on 
the failure to isolate rabies virus from salivary glands of 262 foxes 
without concurrent infection of the CNS, Tierkel (1959) concluded 
that the fox is unable to transmit the disease as a symptomless 
carrier. 
Attempts to control fox rabies have concentrated on the reduction 
of fox populations in epidemic areas. In central Europe,the reduction 
of fox numbers by hunting and gassing of dens has been shown to be a 
valuable approach in the control of fox rabies (Wandeler et al. 1974a, 
b). In the United States, however, the efficacy of using population 
reduction as a technique to control fox rabies is inconsistent. In 
New York, the reduction of fox abundance appears to have reduced the 
incidence of rabies in some areas of the state and intensive trapping 
has virtually eliminated rabies in certain areas (Linhart 1960). 
Virginia instituted a predator control program in 1961 in an effort 
to control sylvatic rabies. "By 1969, the advisability of continuing the 
program was seriously questioned (Carey et al. 1978). They suggested 
that population reduction for the control of rabies may be detrimental 
instead of beneficial because this practice allows a younger, more 
susceptible population to become established. It was estimated that 
70 to 80% of the animals would have to be removed to result in a reduced 
population in a successive year. With the immigration of young animals 
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from surrounding areas, the effects of even severe population reduction 
would be negated. The difficulty involved in the removal of sufficient 
numbers of foxes is magnified by the high cost of removal. Estimated 
costs of $25 to $200 per animal trapped have been reported (Linhart 
1960, Lewis 1968 and Parks 1968). 
It is estimated that a fox population density of greater than 1 
fox per square kilometer is necessary for the establishment of epidemic 
fox rabies (Anon. 1973 and Dean 1955). However, Friend (1968) and 
Carey et al. (1978) suggested that some ecologic barriers can cause 
exceptions to the rule. Parker et al. (1957) found that significantly 
higher fox population densities existed in rabies-free areas of New York 
than existed in rabies-enzootic areas. A similar observation was made 
by Davis and Wood (1959) in Georgia, Florida, and South Carolina. 
Bat rabies 
Bat rabies was first diagnosed in the United States in a Florida 
yellow bat (Dasypterus floridanus) in 1953 (Venters et al. 1954). 
Since that time rabies in bats has been reported in every state of the 
United States except Alaska and Hawaii. Cases of rabies in bats reported 
to CDC are geographically more widely distributed than cases in any 
other animal host (CDC 1977a). The incidence of bat rabies has steadily 
increased from 8 cases in 1953 to 756 cases in 1979 (CDC 1980a). 
In the United States 10 cases of human rabies have been attributed to 
exposure to rabid bats (CDC 1977a). 
Rabies virus has been identified in specimens from 30 of the 39 
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recognized native species of bats (Constantine 1979a). In the United 
States chiropteran rabies is limited to insectivorous bats, but in 
Latin America vampire bats, in the family of Desmodontidae, are 
responsible for hundreds of human deaths and have served as a major 
limiting factor to the livestock industry (Acha 1966 and Bisseru 1972). 
The big brown bat (Eptesicus fuscus), the Mexican free-tailed bat 
(Tadarida brasiliensis mexicana), and various species of the genus 
Myotis are the bat species most frequently reported to be infected in 
the United States (Bigler et al. 1975). 
Although the ultimate importance of bats as vectors of rabies 
is unknown, in terms of both numbers and geographic distribution they 
constitute one of the largest potential reservoirs of the virus in 
the United States today. The majority of the species are gregarious, 
living in colonies of hundreds, sometimes millions, in dark confined 
areas. Other species live as solitary individuals in more open areas 
in tree foliage (Constantine 1979b). 
Infected bats rarely attack man but many persons and pets are 
bitten each year when they handle sick bats (Constantine 1979b). If bats 
prove to be a source of rabies for wild carnivores, they may be a greater 
public health hazard than we realize (Constantine 1979b). 
Another epidemiologically important characteristic of rabies 
infections in bats is the apparent capacity for bats to become latently 
infected and act as carriers of the virus for several months (Burns 
et al. 1956, Sulkin 1962 and Constantine 1971). 
Constantine (1967) theorized that there are two distinct syndromes 
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of species-specific bat rabies—one that does not kill the bat and 
another one that does. He suggested that the nonlethal infection, 
in which neutralizing antibody generally develops, in the absence of 
clinical signs of rabies, is typical of the disease in gregarious bats. 
Occasionally paralysis is observed. He speculated that viral trans­
mission occurs in the course of normal behavior, possibly by aerosol 
or by casual biting (Constantine 1971). Gough and Jorgenson (unpublished 
data; Veterinary Medical Research Institute, Iowa State University) found 
evidence of transplacental infection in big brown bats in Iowa. One 
female bat delivered two young after capture. Rabies viral antigen was 
identified by specific FA antibody examination of impression smears of 
brain tissue of both the mother bat and her 2 infants. The brain of a 
second female captured from the same colony and 2 fetuses removed from 
her uterus also were positive for rabies anticen by FA staining. Sims 
and Sulkin (1963) reported similar findings in fetuses of experimentally 
infected Mexican free-tailed bats. 
The lethal rabies infection in bats occurs more frequently among 
solitary bats. These bats develop furious rabies, attack without 
provocation, and die with encephalitis. This syndrome can be perpe­
trated only if the virus incites these solitary bats to deliberately 
seek out and attack others of their kind (Constantine 1971). 
There is believed to be no strong causal relationship between 
rabies in bats and in rabies in terrestrial animals (Stamm et al. 
1956 and Winkler 1972). However, Winkler (1972) suggested that in 
unique situations where rabid bats are in abnormally close association 
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with other susceptible species, the bats may serve as a reservoir of 
virus for terrestrial animals. Twente (1955) reported heavy prédation 
on bats by raccoons in Kansas qypsum caverns, and Frederickson and 
Thomas (1965) have suggested a relationship between rabies in bats 
and in foxes in caves in Tennessee. 
Constantine, in a series of publications, has reported that 
carnivorous wildlife can be infected with rabies virus after being 
bitten by rabid bats (Constantine 1966c, Constantine and Woodall 1966 
and Constantine et al. 1968), after IM inoculation of isolates of 
bat rabies virus (Constantine 1966 a,b, Constantine and Woodall 1966 and 
Constantine et al. 1968).and by nonbite routes after being exposed 
to the atmosphere of caves inhabited by bats (Constantine 1962). 
Winkler (1968) was able to isolate rabies virus from a bat cave with 
the use of a mechanical air sampler. 
Rabies virus has been isolated from brain, salivary glands, 
mammary glands, and intrascapular brown adipose tissue of bats (Sulkin 
et al. 1959, Sulkin 1962 and Sims and Sulkin 1963). Evidence to suggest 
that viral storage and replication occur in the intrascapular brown fat 
was provided by Sulkin et al. (1959) and Sims and Sulkin (1963). This issue 
is an actively metabolizing source of nutrition during periods of 
hibernation or torpor (Wertheimer and Shapiro 1948 and Remillard 1958). 
Rabies virus was detected in the brown fat of 20 of 20 Mexican free-
tailed bats inoculated with 8000 MICLD50 of rabies virus. Viral titers 
in brown fat ranged from 10 to 1000 MICLD50s (Sims and Sulkin 1963). 
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Bat rabies is most frequently reported in areas of dense human 
populations. This phenomenon can be attributed to a greater potential 
for the infected bat to be observed and subsequently submitted for 
diagnosis of rabies. Constantine (1979b) has found that less than 
0.05% of free ranging bats are harboring the virus. He suggested that 
bites usually occur when curious people handle sick bats and that the 
contact between the public and bats must be prevented. He suggested 
that the frequency of exposure can best be lowered by warning the public 
against handling sick bats and correcting deficiencies in construction 
of buildings that make them accessible to bats. 
Skunk Irabies 
Skunks are the principal wildlife reservoir for rabies in the 
United States. Two species of skunks are of primary importance but, 
as in reporting of fox rabies, little effort has been made to distinguish 
between the skunk species involved. In 1959,Johnson speculated that 
the spotted skunk (Spilogale putorius) was the reservoir for rabies in 
the United States and that the striped skunk (Mephitis mephitis) 
represented an epidemic indicator species. This theory has not been 
widely accepted but rather it is generally believed that the virus is 
maintained and transmitted by striped skunks in broad areas of the 
United States (Friend 1968 and Houseknecht 1969). Currently, more cases 
of rabies in striped skunks are reported than in any other animal species. 
The spotted skunk is found in broad areas of the contiguous United 
States. It is generally absent from the northern tier of the states 
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west of the Mississippi River, the northern two tiers of states east 
of the Mississippi River, and the eastern coastal states except for 
Florida. Striped skunks are found throughout the United States 
(Schwartz and Schwartz 1959). 
It appears that the spotted skunk was important in the dissem­
ination of the disease westward during the early years of the history 
of the disease in wildlife in the United States. The earliest report 
of skunk rabies in the United States was in 1826 by Duhaut-Cilly who 
noted that spotted skunks sometimes entered houses at night, bit people, 
and gave them hydrophobia (Johnson 1959). Johnson (1959) wrote, "The 
human cases of rabies were, for the most part, the result of bites by 
the spotted skunk and this is why this animal is known as the 'phoby 
cat' in the Southwest." 
The current epizootic of skunk rabies appears to have started in 
the early 1950's (Parker 1961). In 1953, there were 319 cases of skunk 
rabies reported in the United States. This made up 4% of the total 
rabies cases reported and 22% of all the wildlife rabies reported for 
that year. In 1979, skunks represented 59% of 5,119 total cases reported 
and 68% of all wildlife rabies reported (CDC 1980a). It can be argued 
that the apparent increased prevalence of skunk rabies is a statistical 
aberration of awareness and reporting, but, while skunk rabies was 
reported 9.5 times more frequently in 1979 than in 1953, fox rabies 
was reported 7.4 times less often (CDC 1978b and 1980a)_ Since the 
reporting of rabies in these 2 species would have similar limitations, 
these figures give some measure of reality to the increase in incidence 
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of skunk rabies in the United States. Factors such as changes in 
population levels and habitat preferences may be involved in the 
apparent shift in relative importance between foxes and skunks. 
Rabid skunks exhibit a broad range of behavioral patterns from 
overtly furious to unusually friendly and docile. While observing an 
epidemic of rabies in a captive skunk colony, Gough and Niemeyer (1975) 
noted that rabid skunks were frequently found dead without any evident 
clinical signs of the disease.having been noted. In an Ohio study of 
95 rabid skunks, 35 instances of lack of coordination and staggering, 
37 instances of viciousness and 25 instances of friendliness were noted. 
Only 5 skunks were reported to be foaming at the mouth (Schnurrenbeqer 
et al. 1964). In observations of 473 rabid skunks in Illinois, 
Schnurrenbeger et al. (1970a) determined the predominant clinical signs 
to be movements during the day time, agressiveness, lack of fear, and 
incoordination. In both the Ohio and the Illinois studies, skunks 
frequently were reported to be attacking dogs. 
Storm and Verts (1966) observed the movements of a naturally 
infected rabid skunk during a radiotelemetric study of skunks in 
Illinois. The animal was apparently normal when the transmitter was 
attached but, when she failed to move for 4 days from an underground 
den, the den was excavated and she was found dead. Thirty-two days 
had elapsed from the date the transmitter was attached until she was 
found dead. Rabies virus was isolated from the skunk's brain and 
salivary gland by mouse inoculation and was identified by the FA 
technique. The skunk had not traveled in a pattern overtly different 
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than that of four nonrabid skunks which also had been equipped with 
radiotransmitters. This is consistent with other reports of movements 
of rabid skunks (Schnurrenberqer et al. 1964 and Schnurrenberqer et al. 
1970a). 
Although rabies in skunks is reported throughout the year, 
generally the majority of cases occur from early spring through 
midsummer (Friend 1968 and Schnurrenberqer et al. 1970a). Secondary 
peaks of skunk rabies are noted in the fall when population densities 
are at a maximum (Friend 1968). Verts (1967) suggested a close 
correlation between the spring and summer peak and the breeding and 
parturition of striped skunks. Communal denning of striped skunks in 
the winter has been suggested as another possible factor in the spread 
of the disease (Parker 1961 and Houseknecht 1969). 
The nematode sinus worm (Skrjabinqylus spp) was considered as a 
potential mode of transmission for rabies virus in skunks. Investi­
gations into the transmission of the virus throughout its life cycle, 
however, indicated that the worm was not involved (Ewing and Hibbs 1966 
and Emmons and Johnson 1969). Beauregard and Casey (1973) ruled out 
the possibility of transmission of rabies by way of the skunk scent 
glands. 
In experimental infections of skunks with rabies virus of fox 
salivary gland origin, Sikes and Tierkel (1960) found that a virus 
titer of 1.4 X 10 MICLD50 was necessary to induce fatal disease in 
skunks inoculated intramuscularly. The incubation period varied from 
17 to 88 days. Clinical illness was observed in the skunks for 1-13 
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days. They found that 15 of 18 skunks which died of rabies had 
detectable virus in their saliva and 3 of these had almost 10® MICLD50 
per 0.03 ml. 
Rabies in skunks in the United States presents a major public health 
hazard. Although direct transmission of rabies virus from wild skunks to 
man is limited, indirect transmission of the virus to man via domestic 
livestock or pets is a major concern. In Iowa, there is a close asso­
ciation between skunks and cattle both on pasture and in feed lots. 
Beran (unpublished data, 1975; College of Veterinary Medicine, Iowa State 
University) reported that in Iowa at least 54 persons underwent rabies 
prophylactic treatment as a result of exposure to rabid cattle for the 
2 year period of 1974-1975. Although skunks are probably the primary 
vector for rabies in cattle in Iowa, on a world wide basis, there are 
only 13 reported cases of human rabies as a result of exposure to rabid 
cattle. Most of the cases could be traced back to rabid foxes and none 
were the result of skunks transmitting rabies to cattle (CDC 1980f). 
Striped skunks are considered by many people to be interesting 
and affectionate pets. However, an increasing number of cases of rabies 
are being reported in wild pets, especially in skunks. In the 3 year 
period of 1977 through 1979, CDC reported that 151 persons were exposed 
to a total of 9 rabid pet skunks in Oklahoma, Montana, Indiana, Arizona 
and Oregon (CDC 1979b). Five persons in New Jersey underwent antirabies 
treatment after exposure to a pet skunk suspected of being rabid 
(Debbie 1979). The sale of and the keeping of skunks as pets is 
strongly discouraged because they are potential sources of rabies. 
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Little direct effort is made to control skunks. Removal of 
garbage and debris around farm buildings and the burning of fence 
rows are possible ways of discouraging habitation by skunks. Indirect 
control of populations occurs when skunks are killed after they are 
caught in traps set for fox, coyote, and raccoon during the trapping 
season. Many more die as a result of highway traffic. 
